US20040038379A1 - Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom - Google Patents
Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom Download PDFInfo
- Publication number
- US20040038379A1 US20040038379A1 US10/603,865 US60386503A US2004038379A1 US 20040038379 A1 US20040038379 A1 US 20040038379A1 US 60386503 A US60386503 A US 60386503A US 2004038379 A1 US2004038379 A1 US 2004038379A1
- Authority
- US
- United States
- Prior art keywords
- abp118
- activity
- strains
- lactobacillus
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000186869 Lactobacillus salivarius Species 0.000 title claims abstract description 57
- 239000004599 antimicrobial Substances 0.000 title claims abstract description 20
- 239000006041 probiotic Substances 0.000 title description 19
- 235000018291 probiotics Nutrition 0.000 title description 19
- 230000000529 probiotic effect Effects 0.000 title description 16
- 230000000694 effects Effects 0.000 claims abstract description 74
- 210000000941 bile Anatomy 0.000 claims abstract description 51
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 36
- 239000006228 supernatant Substances 0.000 claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
- 239000000047 product Substances 0.000 claims abstract description 21
- 244000005700 microbiome Species 0.000 claims abstract description 20
- 210000004051 gastric juice Anatomy 0.000 claims abstract description 18
- 108010067770 Endopeptidase K Proteins 0.000 claims abstract description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 12
- 108010059712 Pronase Proteins 0.000 claims abstract description 10
- 230000003248 secreting effect Effects 0.000 claims abstract description 5
- 230000002368 bacteriocinic effect Effects 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims description 37
- 108010062877 Bacteriocins Proteins 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 30
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 14
- 102000035195 Peptidases Human genes 0.000 claims description 13
- 108091005804 Peptidases Proteins 0.000 claims description 13
- 230000035945 sensitivity Effects 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 10
- 108010053835 Catalase Proteins 0.000 claims description 9
- 239000003599 detergent Substances 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 7
- 229960003085 meticillin Drugs 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- 108090001060 Lipase Proteins 0.000 claims description 6
- 102000004882 Lipase Human genes 0.000 claims description 6
- 239000004367 Lipase Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 235000019421 lipase Nutrition 0.000 claims description 6
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- WBQJTPDOGLYTBE-VIFPVBQESA-N 1-nitroso-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CN(N=O)C2=C1 WBQJTPDOGLYTBE-VIFPVBQESA-N 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 108010027597 alpha-chymotrypsin Proteins 0.000 claims description 5
- 108090000270 Ficain Proteins 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 4
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 4
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 4
- 235000019836 ficin Nutrition 0.000 claims description 4
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 claims description 4
- 229940055729 papain Drugs 0.000 claims description 4
- 235000019834 papain Nutrition 0.000 claims description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 3
- 102100022119 Lipoprotein lipase Human genes 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 102100035882 Catalase Human genes 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 abstract description 67
- 241000894006 Bacteria Species 0.000 abstract description 28
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 7
- 241000186781 Listeria Species 0.000 abstract description 7
- 241000191940 Staphylococcus Species 0.000 abstract description 5
- 230000012010 growth Effects 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 51
- 229920001817 Agar Polymers 0.000 description 42
- 239000008272 agar Substances 0.000 description 41
- 229940039696 lactobacillus Drugs 0.000 description 41
- 235000010633 broth Nutrition 0.000 description 37
- 239000002609 medium Substances 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 30
- 238000004519 manufacturing process Methods 0.000 description 26
- 238000011534 incubation Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 21
- 241000186610 Lactobacillus sp. Species 0.000 description 20
- 239000003613 bile acid Substances 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 241000193749 Bacillus coagulans Species 0.000 description 15
- 101710167313 Drebrin-like protein Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 229940041514 candida albicans extract Drugs 0.000 description 13
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 13
- 239000012138 yeast extract Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 241000894007 species Species 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 241000186840 Lactobacillus fermentum Species 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 235000020183 skimmed milk Nutrition 0.000 description 11
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 10
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 10
- 239000001166 ammonium sulphate Substances 0.000 description 10
- 235000011130 ammonium sulphate Nutrition 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 238000000855 fermentation Methods 0.000 description 10
- 230000004151 fermentation Effects 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 102000016938 Catalase Human genes 0.000 description 8
- 241000589540 Pseudomonas fluorescens Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 7
- 239000004380 Cholic acid Substances 0.000 description 7
- 230000005526 G1 to G0 transition Effects 0.000 description 7
- 239000007836 KH2PO4 Substances 0.000 description 7
- 241001427851 Lactobacillus salivarius UCC118 Species 0.000 description 7
- 241000607142 Salmonella Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 7
- 235000019416 cholic acid Nutrition 0.000 description 7
- 229960002471 cholic acid Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 6
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 6
- 108090000284 Pepsin A Proteins 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 6
- 239000001888 Peptone Substances 0.000 description 6
- 108010080698 Peptones Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 6
- 229960003964 deoxycholic acid Drugs 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 235000019319 peptone Nutrition 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 235000019419 proteases Nutrition 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 5
- QGABLMITFKUQDF-DCAQKATOSA-N Asn-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N QGABLMITFKUQDF-DCAQKATOSA-N 0.000 description 5
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 description 5
- 241000186805 Listeria innocua Species 0.000 description 5
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 4
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 4
- JVACNFOPSUPDTK-QWRGUYRKSA-N Gly-Asn-Phe Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JVACNFOPSUPDTK-QWRGUYRKSA-N 0.000 description 4
- 108010015031 Glycochenodeoxycholic Acid Proteins 0.000 description 4
- 108010007979 Glycocholic Acid Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 244000199866 Lactobacillus casei Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 229940054340 bacillus coagulans Drugs 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 239000003858 bile acid conjugate Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000006161 blood agar Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000005341 cation exchange Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 4
- 229940099347 glycocholic acid Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000003405 ileum Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- SQZIAWGBBUSSPJ-ZKWXMUAHSA-N Asn-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N SQZIAWGBBUSSPJ-ZKWXMUAHSA-N 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 241000334216 Proteus sp. Species 0.000 description 3
- 230000006819 RNA synthesis Effects 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 3
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- GHCZAUBVMUEKKP-GYPHWSFCSA-N glycochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-GYPHWSFCSA-N 0.000 description 3
- 102000052301 human GNAZ Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BHTRKEVKTKCXOH-AYSJQVDDSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-AYSJQVDDSA-N 0.000 description 3
- 239000006150 trypticase soy agar Substances 0.000 description 3
- 239000007195 tryptone soya broth Substances 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- RLMISHABBKUNFO-WHFBIAKZSA-N Ala-Ala-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O RLMISHABBKUNFO-WHFBIAKZSA-N 0.000 description 2
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000589994 Campylobacter sp. Species 0.000 description 2
- 240000001817 Cereus hexagonus Species 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 239000012630 HPLC buffer Substances 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 241000186684 Lactobacillus pentosus Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- ZDBMWELMUCLUPL-QEJZJMRPSA-N Leu-Phe-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 ZDBMWELMUCLUPL-QEJZJMRPSA-N 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FPTXMUIBLMGTQH-ONGXEEELSA-N Phe-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 FPTXMUIBLMGTQH-ONGXEEELSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010025037 T140 peptide Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000007799 cork Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 108010009719 mutanolysin Proteins 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000002278 reconstructive surgery Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- DRTQHJPVMGBUCF-ZVFJYLAJSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5,6-ditritiopyrimidine-2,4-dione Chemical compound [3H]C1=C([3H])C(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DRTQHJPVMGBUCF-ZVFJYLAJSA-N 0.000 description 1
- IPDRTIBDOPMMIQ-VAOFZXAKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(C)O[C@H](CO)[C@@H](O)C1 IPDRTIBDOPMMIQ-VAOFZXAKSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-FOEKBKJKSA-N 3654-96-4 Chemical compound C[35S]CC[C@H](N)C(O)=O FFEARJCKVFRZRR-FOEKBKJKSA-N 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 101710180684 Beta-hexosaminidase Proteins 0.000 description 1
- 101710124976 Beta-hexosaminidase A Proteins 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000206604 Brochothrix thermosphacta Species 0.000 description 1
- WYCRECCWGWCUHS-KABIMGDMSA-N C([C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)C(C)C)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O)C1=CN=CN1 Chemical compound C([C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)C(C)C)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O)C1=CN=CN1 WYCRECCWGWCUHS-KABIMGDMSA-N 0.000 description 1
- 208000031968 Cadaver Diseases 0.000 description 1
- 101100392772 Caenorhabditis elegans gln-2 gene Proteins 0.000 description 1
- 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
- 101100455752 Caenorhabditis elegans lys-3 gene Proteins 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 241000193470 Clostridium sporogenes Species 0.000 description 1
- 241000722863 Cortaderia jubata Species 0.000 description 1
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 1
- 102000030900 Cystinyl aminopeptidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000147019 Enterobacter sp. Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- LUJVWKKYHSLULQ-ZKWXMUAHSA-N Gly-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN LUJVWKKYHSLULQ-ZKWXMUAHSA-N 0.000 description 1
- TVUWMSBGMVAHSJ-KBPBESRZSA-N Gly-Leu-Phe Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 TVUWMSBGMVAHSJ-KBPBESRZSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- QSQXZZCGPXQBPP-BQBZGAKWSA-N Gly-Pro-Cys Chemical compound C1C[C@H](N(C1)C(=O)CN)C(=O)N[C@@H](CS)C(=O)O QSQXZZCGPXQBPP-BQBZGAKWSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606841 Haemophilus sp. Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- GAOJCVKPIGHTGO-UWVGGRQHSA-N Lys-Arg-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O GAOJCVKPIGHTGO-UWVGGRQHSA-N 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- SMFGCTXUBWEPKM-KBPBESRZSA-N Phe-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 SMFGCTXUBWEPKM-KBPBESRZSA-N 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 241001521757 Propionibacterium sp. Species 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 101710081801 Protein O-GlcNAcase Proteins 0.000 description 1
- 241000589538 Pseudomonas fragi Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 101710199095 Putative beta-hexosaminidase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000405383 Salmonella enterica subsp. enterica serovar Typhimurium str. LT2 Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
- NXRAUQGGHPCJIB-RCOVLWMOSA-N Val-Gly-Asn Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O NXRAUQGGHPCJIB-RCOVLWMOSA-N 0.000 description 1
- GQMNEJMFMCJJTD-NHCYSSNCSA-N Val-Pro-Gln Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O GQMNEJMFMCJJTD-NHCYSSNCSA-N 0.000 description 1
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000013272 agar well diffusion method Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 230000001873 bacteriocinogenic effect Effects 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- -1 ceftaxime Chemical compound 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 108010054813 diprotin B Proteins 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 108010066198 glycyl-leucyl-phenylalanine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- SUSRLLXAXAIZPH-OBPIAQAESA-N hydroquinone beta-D-glucopyranoside Natural products OC[C@H]1O[C@@H](Cc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O SUSRLLXAXAIZPH-OBPIAQAESA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 108700018795 salivaricin A Proteins 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 239000007078 todd-hewitt medium Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/179—Sakei
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- This invention relates to probiotic bacterial strains capable of producing antimicrobial agents which have various applications in food stuffs and in medicine. More particularly, the invention relates to probiotic strains of Lactobacillus salivarius and to a peptide antibacterial agent derived therefrom with bacteriocin-like properties.
- the former strain produces the broad spectrum bacteriocin salivaricin B which inhibits the growth of Listeria monocytogenes, Bacillus cereus, Brochothrix thermosphacta, Enterococcus faecalis and many lactobacilli.
- L. acidophilus M46 produces a bacteriocin acidocin B which combines the inhibition of Clostridium sporogenes with a very narrow activity spectrum within the genus Lactobacillus.
- these strains are not indigenous to the infected host species, which is one of the criteria which is required for a successful probiotic strain for human use.
- Salivacin 140 a bacteriocin from Lactobacillus salivarius subsp. salicinius T140.
- Strain T140 was isolated from the surface of Japanese pampas grass leaves grown close to an animal barn and thus the strain was likely to have derived from animal faeces.
- Bacteriocin production by lactobacilli is thought to play an important role in the competitive exclusion of pathogens and other undesirable microorganisms of the intestinal tract of humans.
- Bacteriocins are broadly defined as proteinaceous compounds which exhibit a bactericidal effect against a wide range of microorganisms.
- lactobacilli Due to their diversity of species and habitats lactobacilli are the most bacteriocinogenic of the lactic acid bacteria. As many as forty bacteriocins produced by lactobacilli have now been isolated (Klaenhammer, T. R. (1993) FEMS Microbiol. Rev. 12, 39-86).
- Bacteriocins have been isolated from human infant faeces. However, the bacteriocins were found to have narrow host ranges and were active only against other lactobacillus species (Toba, T. et al. (1991) Lett. Appl. Microbiol. 12, 228-231.).
- the invention provides a strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative microorganisms and which secretes a product having antimicrobial activity into a cell—free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E, the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice.
- the strain of Lactobacillus according to the invention exhibits a broad—spectrum of activity against bacteria including Listeria, Staphylococcus and Bacillus, but does not inhibit many closely related lactobacilli.
- Lactobacillus salivarius strain UCC 1 deposited at The National Collections of Industrial and Marine Bacteria Limited (NCIMB) on Nov. 27, 1996, and accorded the accession number NCIMB 40830
- Lactobacillus salivarius strain UCC 118 deposited at NCIMB on Nov. 27, 1996, and accorded the accession number NCIMB 40829) and mutants or variants thereof having the same properties.
- the antimicrobial product secreted by the Lactobacillus salivarius strains according to the invention may be the expression product of a plasmid or other extrachromosomal entity associated with said strains.
- the invention also provides a health promoting product containing a strain of Lactobacillus salivarius as hereinbefore defined as a probiotic.
- strains of Lactobacillus salivarius according to the invention were isolated from appendices and sections of the large and small intestine of the human gastrointestinal tract (G.I.T.) obtained during reconstructive surgery.
- a preferred site for the isolation of the strains according to the invention is the small intestine. Any bacteria which prove difficult to maintain in culture were discarded as they would not be suitable to work with under processing or manufacturing conditions.
- strains according to the invention when subjected to adhesion assays are found to be highly adherent to both Caco-2 and HT-29 cell-lines.
- the strains of lactobacilli according to the invention are able to survive at pH as low as 2.0. Prior to colonisation and growth of a probiotic in the gastrointestinal tract it must pass through the harsh acidic environment of the stomach. There are four main factors which determine the survival of bacteria on passage through the stomach to reach the intestine, namely the pH of the gastric juice, the buffering capacity of food, the rate of gastric emptying and the quantity and physiological state of the bacterium itself.
- Gastric acid has been implicated as a major host defence mechanism involved in maintaining the sparse bacterial population of the upper small bowel and aiding resistance against infection by pathogenic microorganisms (germicidal activity).
- pathogenic microorganisms pathogenic microorganisms
- a key factor influencing survival of bacteria in gastric juice is pH.
- the lactobacillus strains according to the invention also exhibit high bile resistance. It is considered that resistance to bile acids is an important biological strain characteristic required for survival in the hostile environment of the G.I.T.
- resistance to bile acids is an important biological strain characteristic required for survival in the hostile environment of the G.I.T.
- For microorganisms to have a health-promoting capacity in the human intestine not only must they be able to resist the potentially lethal effects of the bile acids present but they must not impinge on the health of the host by producing toxic compounds such as deoxycholic acid (DCA) and lithocholic acid (LCA) which have been implicated in a number of cytotoxic phenomena.
- DCA deoxycholic acid
- LCDA lithocholic acid
- the invention also provides an antimicrobial agent obtained from a strain of Lactobacillus salivarius according to the invention as hereinbefore defined which has bacteriocin-like properties.
- the antimicrobial agent according to the invention has the following properties:
- Lactobacillus salivarius strains according to the invention namely L. salivarius strains UCC 1 and UCC 118 were screened for antimicrobial activity against a set of four indicator strains, Listeria innocua, Pseudomonas fluorescens, Escherichia coli and Lactobacillus fermentum KLD. These strains when tested on buffered medium were found to be inhibitory towards Listeria innocua and L. fermentum KLD indicator strains. Inhibition studies demonstrated that the two strains inhibited a broad range of Gram positive and Gram negative microorganisms. Both strains secreted antimicrobial activity into the cell-free supernatant and this activity was destroyed by proteinase K and pronase E. Therefore, these compounds were considered to be bacteriocins.
- the L. salivarius strains UCC 1 and UCC 118 produce secretory proteinaceous compounds which have been given the code names ABP1 and ABP118, respectively.
- ABP1 and ABP118 exhibit quite a broad-spectrum of activity against bacteria including Listeria, Staphylococcus and Bacillus but do not inhibit closely related lactobacilli, with the exception of L. fermentum KLD, or other LAB such as Leuconostoc, Streptococcus or Bifidobacterium.
- L. fermentum KLD or other LAB
- Leuconostoc Streptococcus or Bifidobacterium.
- This is an unusual trait of a bacteriocin (Klaenhammer, T. R. (1993) supra), and is likely to be advantageous for the use of these strains as probiotics since they would compete against undesirable microorganisms but not against closely related strains.
- Another unusual feature of the strains is their antagonistic activity towards Pseudomonas sp. This is an unusual trait for Gram positive bacteria.
- UCC strains 1 and 118 have a much broader spectrum of activity than their respective proteinaceous compounds, ABP1 and ABP118. This would suggest that the viable cells produce a product which either enhances or acts in synergy with ABP1/ABP118 to inhibit the target cell.
- ABP1 and ABP118 are not identical bacteriocins (they possess different spectra of inhibition) but are very similar, as both are not active against LAB and each producer is immune to the activity of the other's bacteriocin. Cross immunity may indicate that these bacteriocins act in the same manner.
- ABP118 is active against some methicillin resistant S. aureus (MRSA), H. pylori and P. fluorescens strains. No reports exist to date in the literature of inhibition of MRSA by a bacteriocin.
- the invention also provides a purified fraction of an antimicrobial agent hereinbefore identified as ABP118 and which has the following properties:
- (iv) Comprises an amino acid sequence Asn Met Lys Arg Gly Pro Asn Cys Val Gly Asn Phe Leu Gly Gly Leu Phe Ala Gly Ala Ala Ala Gly Val Pro Gln Gly Pro Cys (SEQ ID NO: 2).
- the antimicrobial agent ABP118 has an unusually broad spectrum of activity as hereinafter described and exemplified.
- the invention also provides a purified fraction of an antimicrobial agent hereinbefore identified as ABP1 and which has the following properties:
- Lactobacillus salivarius strain UCC 118 isolated from human intestine, produces the antibacterial protein, ABP118, which exhibits a broad range of inhibition towards Gram positive and some Gram negative bacteria.
- ABP118 has been shown to be heat stable, resistant over a wide pH range and resistant to treatment with a number of detergents and organic solvents. It is sensitive to proteolytic enzymes and insensitive to lipase activity. Ultrafiltration suggests an apparent molecular weight between 30- and 100-kDa for a crude extract of ABP118. Growth studies demonstrate that maximum production of ABP118 occurs in MRS broth pH 5.5. Removal of either Tween 80 (Trade Mark) or peptones from this medium results in 50% loss in ABP118 production. L.
- salivarius UCC 118 produces ABP118 in milk-based media and in the presence of physiological concentrations of human bile (0.3% (v/v)). Co-culturing experiments demonstrate the ability of L. salivarius UCC 118 to inhibit growth of Salmonella in a broth medium. It is considered that this is due to the production of antimicrobial compounds including ABP118.
- the bacteriocin ABP118 can be detected in an active and available form in the presence of milk proteins.
- milk can be used as a support medium for bacteriocin production in accordance with the invention.
- strains of Lactobacillus salivarius according to the invention can be used for fermenting milk products.
- ABP118 namely pH, temperature and storage stability mean that this bacteriocin is likely to be of value in the food and pharmaceutical industries.
- the antimicrobial agent according to the invention can be used in foodstuffs. It can also be used as a medicament.
- the antimicrobial agent according to the invention is particularly useful against methicillin resistant S. aureus (MRSA).
- the above amino acid sequence (SEQ ID NO: 2), which was determined from a purified fraction of the bacteriocin, is a partial peptide.
- This partial peptide was used to design probes which identified an internal gene sequence and from this sequence an 80 bp fragment was isolated and sequenced.
- This DNA sequence was deduced to give a protein sequence which confirms the identity of SEQ ID NO: 2.
- the invention provides a DNA sequence coding for the bacteriocin ABP118, namely the DNA sequence 5′ATGAAACGCGGACCC AACTGTGTAGGTAACTTCTTAGGTGGTCTATTTGCTGGAGCA GCTGCAGGTGTCCCCCAGGGCCC3′ (SEQ ID NO: 6).
- FIG. 1 is a graphic representation of the survival of washed cells of Lactobacillus strains (cfu/ml) in MRS broth, pH 2.0 versus time (min);
- FIG. 2 is a graphic representation of the survival of washed cells of Lactobacillus strains (cfu/ml) in MRS broth, pH 2.0 versus time (min);
- FIG. 3 is a graphic representation of the survival of Lactobacillus strain UCC 118 (cfu/ml) versus time (min) in unbuffered media and buffered media;
- FIG. 4 is a graphic representation indicating growth of L. salivarius UCC 118 (log OD 600) and production of ABP118 (AU/ml) versus time (h);
- FIG. 5A-FIG. 5D are a graphic representation of the bactericidal effect of ABP118 (5000 AU/ml) on washed (and resuspended in buffer) and unwashed log-, and stationary-phase cells of Bacillus coagulans 1761;
- FIG. 6 is a graphic representation of the growth of Pseudomonas fluorescens in TSAYE broth with ( ⁇ ) and without ( ) addition of ABP118 (5000 AU/ml);
- FIG. 7 is a graphic representation of the growth of methicillin resistant Staphylococcus aureus 148 (MRSA) in TSAYE broth with ( ⁇ ) and without ( ) addition of ABP118 (5000 AU/ml);
- FIG. 8A is a graphic representation of the inhibitory effect of ABP118 on DNA synthesis by Bacillus coagulans 1761.
- FIG. 8B is a graphic representation of the inhibitory effect of ABP118 on RNA synthesis by Bacillus coagulans 1761.
- Frozen tissues were thawed, weighed and placed in cysteinated (0.05%) one quarter strength Ringers' solution. Each sample was gently shaken to remove loosely adhering microorganisms (termed—wash ‘W’). Following transfer to a second volume of Ringers' solution, the sample was vortexed for 7 min to remove tightly adhering bacteria (termed—sample ‘S’). In order to isolate tissue embedded bacteria, samples A, B and C were also homogenised in a Braun blender (termed—homogenate ‘H’).
- the solutions were serially diluted (dilution 10 ⁇ 1 from a wash sample was labelled W1 dilution 10 ⁇ 2 was labelled W2 and the same labelling system was used for the ‘S’ and ‘H’ samples) and spread-plated (100 ⁇ l ) on to the following agar media: RCM (reinforced clostridial media) and RCM adjusted to pH 5.5 using acetic acid; TPY (trypticase, peptone and yeast extract), Chevalier, P. et al. (1990) J. Appl. Bacteriol 68, 619-624).
- MRS deMann, Rogosa and Sharpe
- ROG acetate medium (SL) of Rogosa
- LLA liver-lactose agar of Lapiere
- BHI brain heart infusion agar
- LBS Lactobacillus selective agar
- TSAYE tryptone soya agar supplemented with 0.6% yeast extract. All agar media was supplied by Oxoid Chemicals with the exception of TPY agar. Plates were incubated in anaerobic jars (BBL, Oxoid) using CO 2 generating kits (Anaerocult A, Merck) for 2-5 days at 37° C.
- Gram positive, catalase negative rod-shaped or bifurcated/pleomorphic bacteria isolates were streaked for purity on to complex non-selective media (MRS and TPY). Isolates were routinely cultivated in MRS or TPY medium unless otherwise stated at 37° C. under anaerobic conditions. Presumptive Lactobacillus sp. were stocked in 40% glycerol and stored at ⁇ 20° and ⁇ 80° C.
- Biochemical and physiological traits of the bacterial isolates were determined to aid identification. Nitrate reduction, indole formation and expression of ⁇ -galactosidase activity were assayed. Growth at both 15° C. and 45° C., growth in the presence of increasing concentrations of NaCl up to 5.0% and protease activity on gelatin were determined. Growth characteristics of the strains in litmus milk were also assessed.
- the API 50CHL (BioMerieux SA, France) system was used to tentatively identify the Lactobacillus species by their carbohydrate fermentation profiles. Overnight MRS cultures were harvested by centrifugation and resuspended in the suspension medium provided with the kit. API strips were inoculated and analysed (after 24 and 48 h) according to the manufacturers' instructions. Identity of the Lactobacillus sp. was confirmed by SDS-Polyacrylamide gel electrophoresis analysis (SDS-PAGE) of total cell protein.
- SDS-PAGE SDS-Polyacrylamide gel electrophoresis analysis
- the API ZYM system (BioMerieux, France) was used for semi-quantitative measurement of constitutive enzymes produced by the Lactobacillus isolates.
- Bacterial cells from the late logarithmic growth phase were harvested by centrifugation at 14,000 g for 10 min.
- the pelleted cells were washed and resuspended in 50 mM phosphate buffer, pH 6.8 to the same optical density.
- the strips were inoculated in accordance with the manufacturers' instructions, incubated for 4 h at 37° C. and colour development recorded.
- Antibiotic sensitivity profiles of the isolates were determined using the ‘disc susceptibility’ assay. Cultures were grown up in the appropriate broth medium for 24-48 h, spread-plated (100 ⁇ l) onto agar media and discs containing known concentrations of the antibiotics were placed onto the agar. Strains were examined for antibiotic sensitivity after 1-2 days incubation at 37° under anaerobic conditions. Strains were considered sensitive if zones of inhibition of 1 mm or greater were seen.
- Plasmid profile analysis of ten Lactobacillus sp. was performed using the (Anderson, D. L. and McKay L. L., (1983) Appl. Env. Microbiol. 46, 549-552) lysis procedure with the following modifications. Bacterial cells were inoculated (4%) into 100 ml MRS broth supplemented with 40 mM DL-threonine and incubated for 4-5 h (mid-log phase). Cells, harvested by centrifugation, were used immediately for the plasmid DNA preparation.
- lysozyme (10 mg/ml) and mutanolysin (10 ⁇ g/ml) were added to the cell suspensions and incubated at 37° C. for 1 h and subsequently at 4° C. for 30 min. After the addition of 5 M NaCl, the lysates were put on ice for 30 min. The DNA was electrophoresed on 0.7% vertical agarose. gels in Tris-acetate buffer for 4-5 h at 100V.
- tissue sections taken from the human G.I.T. were screened for the presence of strains belonging to the Lactobacillus genus. There was some variation between tissue samples as follows. Samples A (ileum) and E (appendix) had the lowest counts with approximately 10 2 cells isolated per gram of tissue. In comparison, greater than 10 3 cfu/g tissue were recovered from the other samples. Similar numbers of bacteria were isolated during the ‘wash’ and ‘sample’ steps with slightly higher counts in the ‘sample’ solutions of F (ileum) and G (ileal-caecal). Of those screened for tightly-adhering bacteria (homogenised), C (ileal-caecal) was the only tissue section that gave significant counts.
- API 50CHL allowed rapid identification of the Lactobacillus isolates.
- lactobacilli Antibiotics of human clinical importance were used to ascertain the sensitivity profiles of selected lactobacilli.
- the lactobacilli tested were sensitive to ampicillin, amoxycillin, ceftaxime, ceftriaxone, ciprofloxacin, cephradine, rifampicin and chloramphenicol. They were also resistant to netilmicin, trimethoprim, nalidixic acid, amikacin, vancomycin and gentamicin. Variable sensitivity of the lactobacilli to teicoplanin and ceftizoxime was also observed.
- Lactobacillus strains used were isolated as described in Example 1.
- Human gastric juice was obtained from healthy subjects by aspiration through a nasogastric tube (Mercy Hospital, Cork, Ireland). It was immediately centrifuged at 13,000 g for 30 min to remove all solid particles, sterilised through 0.45 ⁇ m and 0.2 ⁇ m filters and divided into 40 ml aliquots which were stored at 4° C. and ⁇ 20° C.
- Lactobacillus strains were propagated in buffered MRS broth (pH 6.0) daily for a 5 day period. The cells were harvested, washed and resuspended in pH adjusted MRS broth and survival measured over a 2 h period using the plate count method.
- Lactobacillus strains (of human origin) grew normally at pH 6.8 and pH 4.5 reaching stationary phase after 8 h with a doubling time of 80-100 min. At pH 3.5 growth was restricted with doubling times increasing to 6-8 h. No growth was observed at pH 2.5 or lower, therefore, survival of the strains at low pH was examined.
- the Lactobacillus strains were generally resistant to pH values 3.5, 3.0 and 2.5. At pH 2.0, strain variation became apparent (see FIG. 1).
- the Lactobacillus strains of human origin survived with little log reduction for 1 h, however, Lactobacillus 118 had decreased by 2-4 log after 2 h incubation (see FIG. 2).
- Lactobacillus strains used were isolated as described in Example 1.
- Bile samples isolated from several human gall-bladders, were stored at ⁇ 80° C. before use. For experimental work, bile samples were thawed, pooled and sterilised at 80° C. for 10 min. Bile acid composition of human bile was determined using reverse-phase HPLC in combination with a pulsed amperometric detector according to the method of (Dekker, R. R. et al., (1991) Chromatographia 31 (11/12), 255-256). Human bile was added to MRS/TPY agar medium at a concentration of 0.3% (v/v). Freshly streaked cultures were examined for growth after 24 and 48 h.
- Plate assay All the cultures were streaked on MRS/TPY agar plates supplemented with (a) 0.3% (w/v) porcine bile, (b) 3 mM TDCA or (c) 3 mM GDCA. Deconjugation was observed as an opaque precipitate surrounding the colonies (Dashkevicz, M. P., et al. (1989) Appl. Env. Microbiol. 55(1), 11-16).
- a single Lactobacillus colony was inoculated into MRS broth containing 0.3% porcine bile and incubated overnight.
- the culture was centrifuged at 14,000 rpm for 7 min, washed and resuspended in one quarter strength Ringers' solution.
- One hundred microlitres of a 10 ⁇ 3 dilution was spread-plated onto MRS agar plates consisting of a porcine bile gradient from 0.3 to 0.5%. The plates were incubated for 2 days at 37° C. Isolated colonies were picked from the agar sector containing 0.5% porcine bile, restreaked onto MRS supplemented with 0.5% porcine bile and incubated overnight.
- Lactobacillus strains tested were capable of growth (bile acid resistance) on three sources of bile used. It was observed that resistance to bovine bile was much higher than to porcine bile. Lactobacillus strains were resistant to concentrations up to and including 5.0% bovine bile and fourteen of the seventeen strains grew at 7.5%.
- Porcine bile was more inhibitory to all strains as shown in Table 3. TABLE 3 Growth of bacterial isolate in the presence of porcine bile % (w/v) PORCINE BILE STRAIN 0.0 0.3 0.5 1.0 1.5 5.0 7.5 Lactobacillus sp.
- Lactobacillus strains when analysed specifically for their resistance to individual bile acids, grew well in the presence of taurine conjugated bile acids but growth in the presence of glycine conjugated bile acids was variable. Lactobacillus isolates grew to confluence on agar medium containing up to and including 5 mM of taurine conjugates TCA, TDCA and TCDCA. Of the glycine conjugates tested, GCDCA was the most inhibitory, with only four of the Lactobacillus sp. being able to grow at concentrations of 3 mM and 5 mM. GDCA was less inhibitory and GCA was the least inhibitory of the three glycine conjugates as shown in Table 4.
- Bile acid deconjugation activity was confirmed using human bile and HPLC analysis of breakdown products. Only conjugated bile acids were detected in the bile sample.
- a method for the isolation of Lactobacillus strains with increased bile acid resistance Two Lactobacillus strains (4333 and 43310) were chosen which were initially unable to grow in the presence of 0.5% porcine bile but which could grow at a concentration of 0.3% (see. Table 3 above). Following continuous sub-culturing in the presence of increasing concentrations of porcine bile (0.3% to 3.0%), the resistance of strains 4333 and 43310 increased. Strains regularly sub-cultured on MRS agar maintained their induced bile resistance when restreaked onto MRS agar containing 3.0% porcine bile. Furthermore, induced bile resistant strains were subsequently able to deconjugate porcine bile.
- microorganisms screened for antimicrobial production were the seventeen strains listed in Table 3 and were isolated from the human intestinal tract as described in Example 1. All strains belonged to the UCC culture collection
- the indicator microorganisms used in this Example were propagated in the following medium under the following growth conditions: Staphylococcus (37° C., aerobic), Bacillus (37° C., aerobic), Pseudomonas (30° C., aerobic), Escherichia coli (37° C., anaerobic), Salmonella (37° C., anaerobic) and Listeria (30° C., aerobic) in Tryptone Soya broth/agar supplemented with 0.6% yeast extract (TSAYE, Oxoid), Campylobacter (37° C., anaerobic), Bacteroides (37° C., anaerobic), Helicobacter (37° C., anaerobic), Proteus (37° C., anaerobic), Haemophilus (37° C., anaerobic) and Pneumococcus (37° C.,
- the indicator lawn was prepared by inoculating a molten overlay with 2% (v/v) of an overnight indicator culture which was poured over the surface of the inoculated MRS plates. The plates were re-incubated overnight under conditions suitable for growth of the indicator bacterium. Indicator cultures with inhibition zones greater than 1 mm in radius were considered sensitive to the test bacterium.
- the antimicrobial-producing strains L. salivarius 1 and 118, were incubated in MRS broth (800 ml) under anaerobic conditions at 37° C. and cells were harvested at the time of maximum production of antimicrobial activity (usually 6-8 h with a 3% inoculum).
- the supernatant was treated with 40% ammonium sulphate for 1 h at 4° C. with constant agitation, held at 4° C. overnight and then centrifuged at 13,000 g for 30 min.
- the pellet and the pellicle (the layer at the top of the supernatant) were combined and dissolved in 20 ml of phosphate buffer, pH 6.5.
- the solutions were dialyzed against 5 l of phosphate buffer, pH 6.5, for 24 h at 4° C. with 2-3 changes of buffer. Solutions were then filter sterilised, assayed for antimicrobial activity and stored at 4° C. Ammonium sulphate precipitation of the cell-free supernatant at 70% and 100% was also carried out to increase specific activity.
- the inhibitory spectra of lactobacilli were determined by the method of Tagg, J. R. et al. (1976) as described above.
- Cell-free supernatant (CFS) and ammonium sulphate precipitated solution (APS) were also assayed for inhibitory activity against a wide range of Gram positive and Gram negative microorganisms. Overlays of each indicator were prepared on agar plates and allowed to dry. Spots (5 ⁇ l) of CFS and APS were placed on the seeded plates, allowed to dry and plates incubated overnight. The agar well-diffusion method was also employed for the inhibition of Helicobacter , Proteus, Bacteroides and Campylobacter sp.
- Agar plates were either overlayed or swabbed with the indicator organism and allowed to dry.
- Wells (4 mm) were made in the agar plates and CFS (30-40 ⁇ l) was placed in the wells and allowed to diffuse through the agar for 20-40 min at room temperature prior to incubation for 24-48 h after which inhibitory zones were measured.
- Cultures 1 and 118 were spotted onto buffered MRS agar plates containing 0.3% human bile and incubated anaerobically at 37° C. overnight. They were overlayed with indicator strains and incubated for a further 12-18 h. Zones of inhibition greater than 1 mm were considered positive.
- lactobacilli were screened for inhibitory activity using Ls. innocua, L. fermentum KLD, P. fluorescens and E. coli as indicator microorganisms.
- Ls. innocua L. fermentum KLD
- P. fluorescens P. fluorescens
- E. coli indicator microorganisms.
- lactobacilli were seen to inhibit a wide range of both Gram positive and Gram negative indicator microorganisms in both buffered and unbuffered media. Little inhibitory activity was observed towards lactic acid bacteria, such as Streptococcus and other lactobacilli. The inhibitory spectra of L. salivarius 1 and 118 were quite broad. Little inhibition of lactic acid bacteria was observed, however, inhibition of Staphylococcus, Bacillus, Salmonella, E. coli , Pseudomonas and Listeria species was clearly visualized. This inhibition was also produced in the presence of physiological concentrations of human bile.
- CFS and APS of 1 and 118, ABP1 and ABP118 respectively were also tested for inhibitory activity on a wide range of microorganisms and were very active against a number of Gram positive bacteria with ABP118 also being active against the Gram negative microorganism Pseudomonas fluorescens .
- the CFS were not very inhibitory towards other related lactic acid bacteria such as Lactobacillus or the Leuconostoc, Lactococcus, Bifidobacterium or Pediococccus species. Activity was seen against Enterococcus sp. Most noteworthy is the inhibition of strains of Helicobacter pylori and methicillin resistant S. aureus by ABP118 and ABP1 as shown in Table 6.
- Lactobacillus salivarius 118 was isolated, identified and cultured from the human intestinal tract as described in Example 1.
- the indicator microorganisms used in this Example were propagated in Tryptone Soya broth supplemented with 0.6% yeast extract (TSAYE, Oxoid) under the following growth conditions, Bacillus (37° C., aerobic), Escherichia coli (37° C, anaerobic), Salmonella (37° C., anaerobic) and Listeria (30° C., aerobic). All strains were inoculated into fresh growth medium and grown overnight before being used in experiments. Agar sloppies (overlays) and plates were prepared by adding 0.7% (w/v) and 1.5% (w/v) agar to the broth medium, respectively.
- TAYE 0.6% yeast extract
- L. salivarius 118 was grown for 12-16 h in MRS broth and the culture centrifuged at 14,000 g for 10 min.
- Cell-free supernatant (CFS) was spotted (5-10 ⁇ l) onto freshly seeded lawns of Listeria innocua and Bacillus coagulans 1761. Zones of inhibition were measured.
- L. salivarius 118 was grown in broth (800 ml) under anaerobic conditions at 37° C. and cells were harvested after 6-8 h incubation. The supernatant was concentrated using 40% ammonium sulphate for 1 h at 4° C. with constant agitation, held at 4° C. overnight and then centrifuged at 13,000 g for 30 min. The pellet and the pellicle (the layer at the top of the supernatant) were collected and dissolved in a small volume of phosphate buffer, pH 6.5. The solutions were dialyzed against 5 1 of phosphate buffer, pH 6.5, for 24 h at 4° C. with 2-3 changes of buffer. Solutions were then filter sterilised, assayed for antimicrobial activity and stored at 4° C. This was used in the following experiments unless otherwise stated.
- L. salivarius 118 was grown up overnight in MRS broth (50 ml) at 37° C. and then inoculated (2%) into MRS broth (1.5 l) in a fermentation vessel (Model 502D; L. H. Fermentation, Stoke Poges, Bucks.) which was connected to an automatic pH controller, at 37° C., with gentle agitation (200 rpm) and continuously flushed with 5% CO 2 .
- the following pH conditions were imposed in four different experiments: (1) pH 5.5; (2) pH 5.0; (3) pH 4.5 and (4) pH 4.0 and pH was maintained using 8% ammonium hydroxide solution during the experiment.
- pH, OD 600 bacterial counts (cfu/ml) and antimicrobial activity (AU/ml) were recorded over a 24 h period.
- ABP118 was tested for its stability in both alkaline and acidic conditions. pH of the active CFS was adjusted from 1 to 10 using 1N NaOH and HCl. Solutions were filter-sterilised and after incubation for 1 h at room temperature, activity was calculated before and after adjustment using Ls. innocua as the indicator. The pH-adjusted solutions were then readjusted to pH 7 using 1N NaOH and HCl and again incubated for 1 h at room temperature and assayed for AU/ml. Controls used were MRS broth adjusted to the same pH values.
- ABP118 was incubated with the following enzymes (in a 3 to 1 ratio) for 30-60 min and assayed for antimicrobial activity: proteinase K (50 mg/ml, 50 mM KH 2 PO 4 , pH 7.5); pronase E (50 mg/ml, 50 mM KH 2 PO 4 , pH 7.5); trypsin (50 mg/ml, 67 mM Na 2 PO 4 , pH 7.6); ⁇ -chymotrypsin (50 mg/ml.
- proteinase K 50 mg/ml, 50 mM KH 2 PO 4 , pH 7.5
- pronase E 50 mg/ml, 50 mM KH 2 PO 4 , pH 7.5
- trypsin 50 mg/ml, 67 mM Na 2 PO 4 , pH 7.6
- ⁇ -chymotrypsin 50 mg/ml.
- ABP118 was also treated with a number of solvents and detergents for 1-2 h at 37° C.
- the solvents used were, 5% ⁇ -mercaptoethanol; 10% chloroform; 10% acetone; 10% isopropanol; 25% ethanol; 50% acetonitrile; 10% butanol and 50% dichloromethane.
- the detergents used included, Tween 80 (1%), Tween 20 (1%), Triton X-100 (1%), N-laurylsarcosine (1%) and SDS (0.1% and 1%). After incubation the solutions were either dialyzed, vaccum-, or freeze-dried and assayed for activity.
- ABP118 was applied to the ZYM kit (BioMerieux, France) which is used to assay for constitutive enzyme activity (see Example 1 above). To assay for haemolytic and proteolytic activity, ABP118 was spotted (10 ⁇ l) on blood agar and skim milk agar plates, respectively. Reactions were recorded after 24 h and 48 h incubation at 37° C.
- ABP118 was estimated from the cell-free supernatant (CFS) and ammonium sulphate precipitated solution (APS; see Example 4 above) of a L. salivarius 118 culture. Aliquots were ultrafiltered through various membranes (Amicon Inc., MA., USA) including 100-, 30-, 10- and 3 kDa molecular exclusion sizes. Bacteriocin activity was determined in retained and flowthrough fractions.
- MRS broth (100 ml) inoculated (2%) with L. salivarius 118 was incubated at temperatures above that allowing optimal growth (40°, 42° and 45° C.). After 36-48 h growth, broths were serially diluted and spread-plated (100 ⁇ l) onto MRS agar. Colonies were then replicaplated onto MRS agar and MRS agar supplemented with 2% 3-glycerophosphate buffer. Plates were overlayed with sensitive indicator ( B. coagulans 1761) and non-inhibiting colonies were streaked out for purity and stocked in 40% glycerol at ⁇ 20° C. Growth rates of strains and carbohydrate fermentation profiles (API 50CHL) were recorded and compared to that of the wildtype L. salivarius 118.
- API 50CHL carbohydrate fermentation profiles
- ABP118 The inhibitor, ABP118, is protein in nature as it is neutralised by protease enzymes such as pronase E, trypsin and pepsin as shown in Tables 7 and 8 and is also actively secreted in the supernatant.
- protease enzymes such as pronase E, trypsin and pepsin as shown in Tables 7 and 8 and is also actively secreted in the supernatant.
- Protease eliminated antimicrobial activity which was irretrievable after inactivation of the protease.
- ABP118 does not appear to have a lipid component based on the fact that lipase had no effect on activity (see Table 7).
- the compound was active in pH range 1-10 with no reduction in activity (against Ls. innocua ) observed. It is a heat stable protein retaining 100% activity for at least 1 h at 100° C. and with only a 50% loss following severe heat treatment by autoclaving as shown in Table 9.
- TABLE 9 Temperature stability profile of ABP118 Activity of ABP118 % Reduction of Treatment (AU/ml)
- ABP118 activity Untreated 2000 0 121° C. ⁇ 15 min 1000 50 100° C.
- the inhibitor ABP118 was also very stable when stored at 4° C. for 4 months with no loss in activity. Treatment of the compound with a number of organic solvents and detergents did not result in decreased activity as shown in Table 10. TABLE 10 Stability of ABP118 in organic solvents and detergents Activity of ABP118 Treatment (AU/ml) Untreated 2000 Organic solvents Chloroform (10%) 2000 Acetone (10%) 2000 Isopropanol (10%) 2000 Ethanol (25%) 2000 Acetonitrile (50%) 2000 Butanol (10%) 2000 Dichloromethane (50%) 2000 ⁇ -mercaptoethanol (5%) 2000 Detergents Tween 80 (Trade Mark) (1%) 2000 Tween 20 (Trade Mark) (1%) 2000 Triton X (Trade Mark)-100 (1%) 2000 N-laurylsarcosine (1%) 2000 SDS (0.1%) 2000 SDS (1.0%) 1500
- ABP118 was dependent on the phase of growth.
- the kinetics of growth and antimicrobial production by L. salivarius 118 is illustrated in FIG. 4.
- Production of ABP118 was maximal during the logarithmic phase with a reduction in ABP118 concentration during the stationary phase.
- Maximum concentration of ABP118 activity was found when pH was controlled at pH 5.5 with up to 4000 AU/ml being produced after 3-4 h when biomass was quite high.
- pH 4.0 growth of the culture was reduced and ABP118 was not detected.
- MRS and BHI were the two most suitable for support of production of large concentrations of ABP118.
- Tween 80, yeast extract and peptone sources was assayed. Results show that in the absence of any one of these, the concentration of ABP118 reached only 50% that of concentration produced in MRS broth. However, ABP118 activity remained more stable in the medium lacking yeast extract than in any other media tested.
- skim milk-based medium to act as a suitable carrier to support the growth of L. salivarius 118 and production of ABP118 was investigated. Growth in skim milk, skim milk plus yeast extract, and skim milk plus glucose was quite poor. The pH did not go lower than 5.7 after 12 h incubation and little if any ABP118 activity was detected. However, when L. salivarius 118 was grown in skim milk plus yeast extract plus glucose, pH reached a value of 4.4 and 3.87 after 12 and 24 h incubation, respectively. ABP118 activity was detected after 2 h at low levels and the majority of ABP118 (10,000 AU/ml against B. coagulans 1761) was produced by late-log to early-stationary phase of growth. It was also observed that the milk was beginning to clot after 10 h incubation.
- L. salivarius 118 was grown in MRS broth and the culture centrifuged at 14,000 g for 10 min.
- Cell-free supernatant (CFS) was spotted (5-10 ⁇ l) onto freshly seeded lawns of indicator, incubated and zones of inhibition recorded. Activity of the cell-free supernatant was assayed for by a modification of the critical dilution method generally used for assay of bacteriocins (Mayr-Harting et al., (1972) supra).
- Serial dilutions were spotted (5 ⁇ l) onto freshly seeded lawns of Ls. innocua, B. coagulans 1761 and L. fermentum KLD and the plates incubated appropriately.
- the titre was defined as the reciprocal of the highest dilution of inhibitor demonstrating complete inhibition of the indicator lawn and was expressed as activity units (AU) per millilitre (ml).
- Bacteriocin activity was measured during the purification procedure by the microtitre plate assay as described by Holo, H., et al. (1991) J. Bacteriol. 173, 3879-3887. Two-fold serial dilutions of bacteriocin extracts (50 ⁇ l) in TSAYE broth were prepared in microtitre plates (Greiner GmbH, Frickenhausen). One hundred and fifty microlitres of fresh indicator culture (A 600 ⁇ 0.1) and 50 ⁇ l of TSAYE were added and the plates incubated at 37° C. Growth of the indicator strain was measured spectrophotometrically at 600 nm. One bacteriocin unit was defined as the amount of bacteriocin causing 50% growth inhibition (50% of the turbidity of the control culture without bacteriocin) in this assay.
- L. salivarius 118 was grown to the late logarithmic phase in 2 l of MRS broth (Oxoid) and centrifuged at 12,000 rpm for 20 min. Ammonium sulphate (300 g/l) was added to the cell-free supernatant, stirred at 4° C. for 1 h, and centrifuged at 8,000 rpm for 30 min. The pellet and pellicle (floating solid material) were combined and dissolved in 100 ml H 2 O (Fraction I).
- Fraction I Fraction I was mixed with 10 g of amberlite XAD-16 (Supelco) for 30-45 min applied to a column and washed once with H 2 O (100 ml) and then twice with 40% ethanol (100 ml). The bacteriocin was eluted from the column with 100 ml (10 ⁇ 10 ml) of 70% isopropanol-10 mM HCl (Fraction II).
- Fraction II was adjusted to pH 2-3 with H 2 O+0.1% trifluoroacetic acid (TFA) and immediately applied to a 2 ml S-Sepharose Fast Flow cation exchange column previously equilibrated with 5 mM sodium phosphate buffer, pH 5.4 (buffer A). After subsequent washing with 40 ml of buffer A, the bacteriocin was eluted with 20 ml of 1 M NaCl in buffer A (Fraction III).
- TFA trifluoroacetic acid
- Fraction III was applied to a C 2 /C 18 reverse-phase FPLC column (Pep RPC) equilibrated with isopropanol containing 0.1% TFA, solution A.
- the bacteriocin was eluted with a linear gradient ranging from 30-37% solution A for 40 min. followed by a gradient 37-100% solution A for another 5 min.
- the flow rate was 0.5 ml/min and 1 ml fractions were collected. Each fraction was tested for activity using the microtitre plate assay. Fractions with high bacteriocin activity were mixed and rechromatographed on the reverse-phase column.
- the purified bacteriocin was hydrolyzed and analyzed on an amino acid analyzer as described previously (Fykse, E. M., et al., (1988) Biochem J. 256, 973-980).
- the amino acid sequence was performed by Edman degradation with an Applied Biosystems model 477A automatic sequencer with an on-line 120A phenylthriohydantoin amino acid analyser (Cornwell, G. G., et al., (1988) Biochem. Biophys. Res. Commun.
- ABP118 ability of ABP118 to adsorb to the cell wall of sensitive and resistant strains was investigated. Briefly, three overnight cultures of Ls. innocua, L. salivarius UCC 118, L. fermentum KLD, E. coli 1266 and B. coagulans 1761 were each subcultured in fresh broth (20 ml) and grown to mid-logarithmic phase. Cells were harvested by centrifugation, washed twice in 50 mM sodium phosphate buffer, pH 6.5, and resuspended in buffers pH 4.0, 6.0 and 8.0 containing 2000 AU/ml of ABP118. The mixtures were incubated at 37° C. for 2 h. The cells were then removed by centrifugation and the antimicrobial titre of the supernatant was determined. Controls included incubation of 2000 AU/ml of ABP 118 with no cells and cells with no ABP 118 added.
- Duplicates of Ls. innocua, L. fermentum KLD and B. coagulans 1761 were grown to log-phase (OD 600 , 0.2-0.5). To one set of cells 5000 AU/ml of ABP118 was added. The second set of cells were washed twice and resuspended in phosphate buffer, pH 6.5 prior to the addition of 5000 AU/ml of ABP118. Growth (cfu/ml) under the appropriate conditions, was monitored for a further 7-8 h. This experiment was repeated using stationary-phase cells.
- the sensitive indicator B. coagulans 1761 was inoculated (3% (v/v)) into TSAYE growth medium and grown to early log phase (3-4 h) at 37° C. The culture was divided in two. To one half 5000 AU/ml of antimicrobial compound was added while an equivalent volume of growth medium was added to the other half. Each half was then supplemented with a radiolabelled substrate. The following substrates (New England Nuclear Corporation.) were used: [5,6- 3 H]uridine (39.6 Ci/mmol) at 5 ⁇ Ci/ml;.
- ABP118 which is produced in the log-phase of growth (see Example 5), was concentrated 20-fold from culture media by ammonium sulphate precipitation (Fraction I) resulting in a 292-fold increase in specific activity with a recovery of 250% as shown in Tables 11 and 12. TABLE 11 Purification of ABP118 Vol. Total* Total act. Purification stage (ml) A 280 (BU) Culture supernatant 2000 54,800 5,120,000 Fraction I Ammonium suphate ppt. 470 12,800,000 II Hydrophobic 51 192,000 (interaction (XAD-16) III Cation exchange 5.98 6,400 IVC 2 /C 18 Reverse-phase 1.5 0.192 2,400 FPLC
- amino acid composition of pure ABP118 was determined as shown in Table 13. TABLE 13 Amino acid composition of ABP118 Amino acid residues/molecules Asp/Asn 4 Glu/Gln 2 Ser 1-2 Gly 8-10 His 0-1 Arg 2 Thr 2 Ala* 6 Pro* 4 Met* 1 Cys 1 Ile* 1 Leu* 5 Phe* 2 Lys 2 Val 2 Total 43-47
- Adsorption of ABP118 was tested over the pH range 4.0-8.0. It was observed that ABP118 bound to the sensitive cells tested (see Table 14) but not to the resistant producer strain L. salivarius UCC 118. TABLE 14 Adsorption of ABP118 (1600 AU/ml) to sensitive and resistant cells under different pH conditions* ABP118 (AU/ml) unadsorbed Strain pH 4.0 pH 6.0 pH 8.0 Lactobacillus 1000 (40%) 800 (50%) 800 (50%) fermentum KLD (S) L.
- ABP118 binding to E. coli 1266 was observed at pH 8.0 but not at the lower pH values tested. After 2 h incubation at 37° C., 40% adsorption of ABP118 to sensitive cells was measured, Total adsorption of 100% was never observed. Less adsorption was found when the experiment was repeated at 4° C. When cells were autoclaved, 40% adsorption was recorded for both sensitive and resistant cells. When cells were treated with protease there was little increase in adsorption to either sensitive or resistant cells.
- ABP118 Possesses both Bactericidal and Bacteriostatic Activity:
- the inhibitor ABP118 is bactericidal in nature. The most impressive example of this was the effect ABP118 had on the growth of B. coagulans 1761 during both the log-, and stationary-phase of growth (on both unwashed and washed cells; see FIGS. 5 A- 5 D). The broth cleared during the first couple of hours after addition of ABP118 demonstrating the lytic activity of ABP118. The bactericidal activity towards Ls. innocua and L. fermentum KLD was more evident in the log-phase of growth than in the stationary-phase. It was noticed that a rapid decline in KLD strain cell viability occurred after incubation of stationary-phase cells for 4 h after the addition of ABP118.
- ABP118 The activity of ABP118 (5000 AU/ml) was also tested against a Gram negative P. fluorescens strain and a methicillin resistant S. aureus strain. After 60-90 min incubation a bacteriostatic effect on the growth of both strains was clearly evident (FIGS. 6 and 7). After 1 h incubation at 30/37° C. the cells were divided in two, ABP118 added to one portion (arrows), and growth was monitored for a further 8-9 h. The line ⁇ - ⁇ illustrates the bacteriostatic effect of ABP118.
- ABP118 Inhibits DNA and RNA Synthesis:
- Example 6 The procedure followed in Example 6 in obtaining the amino acid composition for ABP118 was repeated so as to determine the amino acid composition of pure ABP1.
- the amino acid composition is shown in Table 15. TABLE 15 Amino acid composition of ABP1 Amino acid residues/molecules Asp/Asn 5 Glu/Gln 6 Ser 5-6 Gly 8-9 His 1 Arg 2-3 Thr 2 Ala* 4-5 Pro* 2 Ile* 1-2 Leu* 3 Phe* 1 Lys 3 Tyr 1 Val* 2-3 Total 46-52
- ABP118 no unusual amino acids were detected. A high proportion of glycine and alanine was found and a relatively high proportion of leucine. No trytophan was found, however tyrosine and valine were found. Of the 46-52 amino acids, 13-16 were hydrophobic.
- Total genomic DNA was isolated from UCC118 grown in MRS supplemented with 40 mM DL-threonine by the method of Leenhouts et al. 1991 (J. Bacteriol. 173:4794-4798) and purified by CsCl-ethidium bromide buoyant density gradient centrifugation, with the following modifications. After pelleting and washing the cells in STE buffer, pH 8.0 (6.7% Sucrose, 50 mM Tris/HCl. ImM EDTA), the repelleted cells were stored at ⁇ 20° C. o/n.
- the cells were lysed using 8 mg/ml lysozyme and 50 U/ml mutanolysin on ice for 1 hour and then incubated at 37° C. for 45 minutes. Before adding SDS solution, 2 mg/ml of proteinase K was added and incubated at 55° C. for 1 hour.
- pGEM-T recombinants were identified by blue-white screening, using isopropyl- ⁇ -D-thiogalactoside and 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactoside (X-gal). The presence of inserts was confirmed by PCR using the pGEM-T sequencing primers designed to the known sequences of the T7 and SP6 promoters. These PCR amplified fragments were sequenced by the automated DNA sequencer 373 stretch XL (PE Applied Biosystems) using the Dye terminator cycle sequencing ready reaction kit with Ampli Taq DNA polymerase, FS (Applied Biosystems).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Abstract
A strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract inhibits a broad range of Gram positive and Gram negative microorganisms and secretes a product having antimicrobial activity into a cell-free supernatant. The activity is produced only by growing cells and is destroyed by proteinase K and pronase E, the inhibitory properties of the strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice. The strain exhibits a broad-spectrum of activity against bacteria including Listeria, Staphylococcus, including methocillin resistant St. aureus (MRSA), and Bacillus, but does not inhibit many closely related lactobacilli. An antimicrobial agent is obtained from the strain which has bacteriocin-like properties.
Description
- This application is a divisional of co-pending application Ser. No. 09/367,105, filed on Nov. 10, 1999, and for which priority is claimed under 35 U.S.C. § 120. application Ser. No. 09/367,105 is the national phase o f PCT International Application No. PCT/IE98/00010 filed on Feb. 11, 1998, under 35 U.S.C. § 371. The entire contents of each of the above-identified applications are hereby incorporated by reference. This application also claims priority of International Application No. PCT/IE97/00007 filed on Feb. 11, 1997, under 35 U.S.C. § 119.
- This invention relates to probiotic bacterial strains capable of producing antimicrobial agents which have various applications in food stuffs and in medicine. More particularly, the invention relates to probiotic strains ofLactobacillus salivarius and to a peptide antibacterial agent derived therefrom with bacteriocin-like properties.
- Much research has been carried out in the field of human probiotics in the last decade (see review Huis in't Veld et al. (1994)Tibtech 12, 6-8). This research has been prompted by the rising interest by the public in their health and well-being. Many probiotic products are now available on the market and some of the beneficial effects derived from these products range from alleviation of lactose intolerance (Gilliland, S. E. (1990) FEMS Microbiol. Rev. 87, 175-188) to prevention of diarrheal diseases (Marteau, P. et al. (1993) FEMS Microbiol. Rev. 12, 207-220) and possible prevention of carcinogenesis (Adachi, S. (1992) In “The Lactic Acid Bacteria in Health and Disease”. (Wood, Ed.), 233-262, Elsevier, Barking). Controversy exists over many of these beneficial effects as no standardised procedures are available and contradictory results have been published with regard to the possible beneficial effects of cultured products containing ‘probiotic’ bacteria.
- Poor choice of strain has been cited as one of the contributing factors to the inconsistency and variability of results (Marteau, P. et al. (1993) supra) (Kim, H. S. (1988) Cult. Dairy Prod.J. 23, 6-9) and Fuller, R. ((1989) J. Appl. Bact. 66, 365-378) outlined criteria pertaining to the successful isolation of probiotic strains. The strains should be indigenous to the intended host species and also have the ability to (i) survive and grow within that host; (ii) exert a beneficial effect at the target site and (iii) be maintainable in the carrier food or system throughout product manufacture and storage.
- There is a fast growing market for health-promoting products including probiotics. Many such products are now available (Jong, S. C. and Birmingham, J. M., (1993)ATCC Quart. Newslett. 13(1), 1-11). One of the more important components of these products is the microorganisms used. The most frequently utilised species include Bifidobacterium sp., Lactobacillus sp., and Propionibacterium sp. (O'Sullivan, M. G., et al. (1992) Trends in Food Sci. and Tech. 3(12), 309-314). There is a lack of substantiated evidence from controlled trials that the organisms currently used in such products are those which have beneficial effects on the gut flora (Tannock, G. W. (1983) In Human Intestinal Microflora in Health and Disease 517-539 D. J. Hentges (ed.), New York, Academic Press). The source of the microorganism is critical to its survival and therefore its function in the human intestinal tract. Lee, Y -K and Salminen, S. ((1995) Trends Food Sci. Technol. 6, 241-245) stated that as a general requirement, a probiotic strain should be of human origin as some health-promoting effects may be species dependent. It is well known that the indigenous microflora is one of the major defense mechanisms that protects the human against colonisation by allochthonous invading bacteria (Tancrede, C. (1992) Eur. J. Clin. Microbiol. Infect. Dis. 11(11), 1012-1015) and it is also the human's best ally when supporting the immune system. Bacterial populations at different levels of the gastrointestinal tract constitute complex ecosystems depending on the physiology of the host and on interactions between bacteria.
- Ten Brink et al. ((1994) Journal of Applied Bacteriology 77 140-148) isolated and screened a large number (˜1000) of Lactobacillus strains for the production of antimicrobial activity. Lactobacilli were isolated from various fermented foods and feeds (sauerkraut, cheese, sausage and silage), human dental plaque and faeces derived from different laboratory animals (rat, mouse, guinea pig and quail) and human volunteers. Only eight positive strains were found and two of these were studied, namelyLactobacillus salivarius M7 and Lactobacillus acidophilus M46. The former strain produces the broad spectrum bacteriocin salivaricin B which inhibits the growth of Listeria monocytogenes, Bacillus cereus, Brochothrix thermosphacta, Enterococcus faecalis and many lactobacilli. L. acidophilus M46 produces a bacteriocin acidocin B which combines the inhibition of Clostridium sporogenes with a very narrow activity spectrum within the genus Lactobacillus. However, these strains are not indigenous to the infected host species, which is one of the criteria which is required for a successful probiotic strain for human use.
- Arihara, K. et al. ((1996) Letters in Applied Microbiology 22, 420-424) have isolated Salivacin 140 a bacteriocin fromLactobacillus salivarius subsp. salicinius T140. Strain T140 was isolated from the surface of Japanese pampas grass leaves grown close to an animal barn and thus the strain was likely to have derived from animal faeces.
- There is a need for probiotic strains which meet the aforementioned criteria. Bacteriocin production by lactobacilli is thought to play an important role in the competitive exclusion of pathogens and other undesirable microorganisms of the intestinal tract of humans. Bacteriocins are broadly defined as proteinaceous compounds which exhibit a bactericidal effect against a wide range of microorganisms.
- Due to their diversity of species and habitats lactobacilli are the most bacteriocinogenic of the lactic acid bacteria. As many as forty bacteriocins produced by lactobacilli have now been isolated (Klaenhammer, T. R. (1993)FEMS Microbiol. Rev. 12, 39-86).
- Bacteriocins have been isolated from human infant faeces. However, the bacteriocins were found to have narrow host ranges and were active only against other lactobacillus species (Toba, T. et al. (1991)Lett. Appl. Microbiol. 12, 228-231.).
- There is a need for bacteriocins with a broad spectrum of activity.
- The invention provides a strain ofLactobacillus salivarius isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative microorganisms and which secretes a product having antimicrobial activity into a cell—free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E, the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice.
- Preferably, the strain of Lactobacillus according to the invention exhibits a broad—spectrum of activity against bacteria including Listeria, Staphylococcus and Bacillus, but does not inhibit many closely relatedlactobacilli.
- Two especially preferred strains areLactobacillus salivarius strain UCC 1 (deposited at The National Collections of Industrial and Marine Bacteria Limited (NCIMB) on Nov. 27, 1996, and accorded the accession number NCIMB 40830) and Lactobacillus salivarius strain UCC 118 (deposited at NCIMB on Nov. 27, 1996, and accorded the accession number NCIMB 40829) and mutants or variants thereof having the same properties.
- The antimicrobial product secreted by theLactobacillus salivarius strains according to the invention may be the expression product of a plasmid or other extrachromosomal entity associated with said strains.
- The invention also provides a health promoting product containing a strain ofLactobacillus salivarius as hereinbefore defined as a probiotic.
- The strains ofLactobacillus salivarius according to the invention were isolated from appendices and sections of the large and small intestine of the human gastrointestinal tract (G.I.T.) obtained during reconstructive surgery.
- A preferred site for the isolation of the strains according to the invention is the small intestine. Any bacteria which prove difficult to maintain in culture were discarded as they would not be suitable to work with under processing or manufacturing conditions.
- In this way certain strains ofLactobacillus salivarius were identified which have a greater chance of survival in the human G.I.T. when compared to many of the probiotic strains currently being used.
- The strains according to the invention when subjected to adhesion assays are found to be highly adherent to both Caco-2 and HT-29 cell-lines.
- The strains of lactobacilli according to the invention are able to survive at pH as low as 2.0. Prior to colonisation and growth of a probiotic in the gastrointestinal tract it must pass through the harsh acidic environment of the stomach. There are four main factors which determine the survival of bacteria on passage through the stomach to reach the intestine, namely the pH of the gastric juice, the buffering capacity of food, the rate of gastric emptying and the quantity and physiological state of the bacterium itself.
- Gastric acid has been implicated as a major host defence mechanism involved in maintaining the sparse bacterial population of the upper small bowel and aiding resistance against infection by pathogenic microorganisms (germicidal activity). A key factor influencing survival of bacteria in gastric juice is pH.
- The mechanism of tolerance of a probiotic strain to low pH is of importance for its ability to survive passage through the stomach. Prolonged incubation of the cells of the lactobacillus strains according to the invention in buffered media prior to challenge at low pH values show that they are sensitive to pH 2.0. This observation indicates that these strains possess an inducible acid tolerance mechanism for resistance as hereinafter exemplified.
- The lactobacillus strains according to the invention also exhibit high bile resistance. It is considered that resistance to bile acids is an important biological strain characteristic required for survival in the hostile environment of the G.I.T. For microorganisms to have a health-promoting capacity in the human intestine not only must they be able to resist the potentially lethal effects of the bile acids present but they must not impinge on the health of the host by producing toxic compounds such as deoxycholic acid (DCA) and lithocholic acid (LCA) which have been implicated in a number of cytotoxic phenomena.
- The invention also provides an antimicrobial agent obtained from a strain ofLactobacillus salivarius according to the invention as hereinbefore defined which has bacteriocin-like properties.
- Preferably, the antimicrobial agent according to the invention has the following properties:
- (i) An apparent molecular weight between 30 and 100 kDa;
- (ii) Heat stability;
- (iii) Resistance over a wide pH range;
- (iv) Resistance to treatment with detergents;
- (v) Resistance to organic solvents;
- (vi) Sensitivity to proteolytic enzymes including proteinase K, pronase E, trypsin, α-chymotrypsin, ficin and papain; and
- (vii) Resistance to lipase, catalase, alkaline phosphatase, phospholipase C and lipoprotein lipase.
- Two of theLactobacillus salivarius strains according to the invention, namely L. salivarius strains
UCC 1 andUCC 118 were screened for antimicrobial activity against a set of four indicator strains, Listeria innocua, Pseudomonas fluorescens, Escherichia coli and Lactobacillus fermentum KLD. These strains when tested on buffered medium were found to be inhibitory towards Listeria innocua and L. fermentum KLD indicator strains. Inhibition studies demonstrated that the two strains inhibited a broad range of Gram positive and Gram negative microorganisms. Both strains secreted antimicrobial activity into the cell-free supernatant and this activity was destroyed by proteinase K and pronase E. Therefore, these compounds were considered to be bacteriocins. - TheL. salivarius strains
UCC 1 andUCC 118 produce secretory proteinaceous compounds which have been given the code names ABP1 and ABP118, respectively. - ABP1 and ABP118 exhibit quite a broad-spectrum of activity against bacteria including Listeria, Staphylococcus and Bacillus but do not inhibit closely related lactobacilli, with the exception ofL. fermentum KLD, or other LAB such as Leuconostoc, Streptococcus or Bifidobacterium. This is an unusual trait of a bacteriocin (Klaenhammer, T. R. (1993) supra), and is likely to be advantageous for the use of these strains as probiotics since they would compete against undesirable microorganisms but not against closely related strains. Another unusual feature of the strains is their antagonistic activity towards Pseudomonas sp. This is an unusual trait for Gram positive bacteria.
- UCC strains 1 and 118 have a much broader spectrum of activity than their respective proteinaceous compounds, ABP1 and ABP118. This would suggest that the viable cells produce a product which either enhances or acts in synergy with ABP1/ABP118 to inhibit the target cell.
- ABP1 and ABP118 are not identical bacteriocins (they possess different spectra of inhibition) but are very similar, as both are not active against LAB and each producer is immune to the activity of the other's bacteriocin. Cross immunity may indicate that these bacteriocins act in the same manner. ABP118 is active against some methicillin resistantS. aureus (MRSA), H. pylori and P. fluorescens strains. No reports exist to date in the literature of inhibition of MRSA by a bacteriocin.
- The invention also provides a purified fraction of an antimicrobial agent hereinbefore identified as ABP118 and which has the following properties:
- (i) A molecular weight of 5.0-5.3 kDa;
- (ii) A relative amino acid composition which has greater than 45% of hydrophobic amino acids, 19-21% glycine, 13-14% alanine and 11-12% leucine, no tryptophan or tyrosine, one methionine and four proline residues;
- (iii) An amino acid sequence -Lys-Arg-Gly-Pro-Asn-C (SEQ ID NO: 1) at or adjacent to the N-terminus; and
- (iv) Comprises an amino acid sequence Asn Met Lys Arg Gly Pro Asn Cys Val Gly Asn Phe Leu Gly Gly Leu Phe Ala Gly Ala Ala Ala Gly Val Pro Gln Gly Pro Cys (SEQ ID NO: 2).
- The antimicrobial agent ABP118 has an unusually broad spectrum of activity as hereinafter described and exemplified.
- The invention also provides a purified fraction of an antimicrobial agent hereinbefore identified as ABP1 and which has the following properties:
- (i) A molecular weight of 5.3-6.1 kDa; and
- (ii) A relative amino acid composition which has greater than 28-30% of hydrophobic amino acids, 17% glycine and 12-13% alanine, no tryptophan and two proline residues.
- As indicated above,Lactobacillus
salivarius strain UCC 118, isolated from human intestine, produces the antibacterial protein, ABP118, which exhibits a broad range of inhibition towards Gram positive and some Gram negative bacteria. ABP118 has been shown to be heat stable, resistant over a wide pH range and resistant to treatment with a number of detergents and organic solvents. It is sensitive to proteolytic enzymes and insensitive to lipase activity. Ultrafiltration suggests an apparent molecular weight between 30- and 100-kDa for a crude extract of ABP118. Growth studies demonstrate that maximum production of ABP118 occurs in MRS broth pH 5.5. Removal of either Tween 80 (Trade Mark) or peptones from this medium results in 50% loss in ABP118 production.L. salivarius UCC 118 produces ABP118 in milk-based media and in the presence of physiological concentrations of human bile (0.3% (v/v)). Co-culturing experiments demonstrate the ability ofL. salivarius UCC 118 to inhibit growth of Salmonella in a broth medium. It is considered that this is due to the production of antimicrobial compounds including ABP118. - The bacteriocin ABP118 can be detected in an active and available form in the presence of milk proteins. Thus, milk can be used as a support medium for bacteriocin production in accordance with the invention. Furthermore, the strains ofLactobacillus salivarius according to the invention can be used for fermenting milk products.
- The above mentioned properties of ABP118, namely pH, temperature and storage stability mean that this bacteriocin is likely to be of value in the food and pharmaceutical industries.
- Thus, the antimicrobial agent according to the invention can be used in foodstuffs. It can also be used as a medicament.
- The antimicrobial agent according to the invention is particularly useful against methicillin resistantS. aureus (MRSA).
- As hereinafter demonstrated in Examples 7 and 8, the above amino acid sequence (SEQ ID NO: 2), which was determined from a purified fraction of the bacteriocin, is a partial peptide. This partial peptide was used to design probes which identified an internal gene sequence and from this sequence an 80 bp fragment was isolated and sequenced. This DNA sequence was deduced to give a protein sequence which confirms the identity of SEQ ID NO: 2. Thus, the invention provides a DNA sequence coding for the bacteriocin ABP118, namely the
DNA sequence 5′ATGAAACGCGGACCC AACTGTGTAGGTAACTTCTTAGGTGGTCTATTTGCTGGAGCA GCTGCAGGTGTCCCCCAGGGCCC3′ (SEQ ID NO: 6). - FIG. 1 is a graphic representation of the survival of washed cells of Lactobacillus strains (cfu/ml) in MRS broth, pH 2.0 versus time (min);
- FIG. 2 is a graphic representation of the survival of washed cells of Lactobacillus strains (cfu/ml) in MRS broth, pH 2.0 versus time (min);
- FIG. 3 is a graphic representation of the survival of Lactobacillus strain UCC 118 (cfu/ml) versus time (min) in unbuffered media and buffered media;
- FIG. 4 is a graphic representation indicating growth ofL. salivarius UCC 118 (log OD 600) and production of ABP118 (AU/ml) versus time (h);
- FIG. 5A-FIG. 5D are a graphic representation of the bactericidal effect of ABP118 (5000 AU/ml) on washed (and resuspended in buffer) and unwashed log-, and stationary-phase cells of
Bacillus coagulans 1761; -
-
- FIG. 8A is a graphic representation of the inhibitory effect of ABP118 on DNA synthesis by
Bacillus coagulans 1761; and - FIG. 8B is a graphic representation of the inhibitory effect of ABP118 on RNA synthesis by
Bacillus coagulans 1761. - The invention will be further illustrated by the following Examples.
- Isolation of Probiotic Bacteria
- Appendices and sections of the large and small intestine of the human G.I.T., obtained during reconstructive surgery, were screened for probiotic bacterial strains as shown in Table 1.
TABLE 1 Gastrointestinal tract tissue samples screened for the presence of probiotic bacteria Sample Location A Ileum B Colon C Ileal-caecal region D Appendix E Appendix F Ileum G Ileal-caecal region - All samples were stored immediately after surgery at −80° C. in sterile containers.
- Frozen tissues were thawed, weighed and placed in cysteinated (0.05%) one quarter strength Ringers' solution. Each sample was gently shaken to remove loosely adhering microorganisms (termed—wash ‘W’). Following transfer to a second volume of Ringers' solution, the sample was vortexed for 7 min to remove tightly adhering bacteria (termed—sample ‘S’). In order to isolate tissue embedded bacteria, samples A, B and C were also homogenised in a Braun blender (termed—homogenate ‘H’). The solutions were serially diluted (
dilution 10−1 from a wash sample was labelledW1 dilution 10−2 was labelled W2 and the same labelling system was used for the ‘S’ and ‘H’ samples) and spread-plated (100 μl ) on to the following agar media: RCM (reinforced clostridial media) and RCM adjusted to pH 5.5 using acetic acid; TPY (trypticase, peptone and yeast extract), Chevalier, P. et al. (1990) J. Appl. Bacteriol 68, 619-624). MRS (deMann, Rogosa and Sharpe); ROG (acetate medium (SL) of Rogosa); LLA (liver-lactose agar of Lapiere); BHI (brain heart infusion agar); LBS (Lactobacillus selective agar) and TSAYE (tryptone soya agar supplemented with 0.6% yeast extract). All agar media was supplied by Oxoid Chemicals with the exception of TPY agar. Plates were incubated in anaerobic jars (BBL, Oxoid) using CO2 generating kits (Anaerocult A, Merck) for 2-5 days at 37° C. - Gram positive, catalase negative rod-shaped or bifurcated/pleomorphic bacteria isolates were streaked for purity on to complex non-selective media (MRS and TPY). Isolates were routinely cultivated in MRS or TPY medium unless otherwise stated at 37° C. under anaerobic conditions. Presumptive Lactobacillus sp. were stocked in 40% glycerol and stored at −20° and −80° C.
- Fermentation End-Product Analysis
- Metabolism of the carbohydrate glucose and the subsequent organic acid end-products were examined using an LKB Bromma, Aminex HPX-87H High Performance Liquid Chromatography (HPLC) column. The column was maintained at 60° C. with a flow rate of 0.6 ml/min (constant pressure). The HPLC buffer used was 0.01 N H2SO4. Prior to analysis, the column was calibrated using 10 mM citrate, 10 mM glucose, 20 mM lactate and 10 mM acetate as standards. Cultures were propagated in modified MRS broth for 1-2 days at 37° C. anaerobically. Following centrifugation for 10 min at 14,000 g, the supernatant was diluted 1:5 with HPLC buffer and 200 μl was analysed in the HPLC. All supernatants were analysed in duplicate.
- Biochemical and Physiological Characterisation
- Biochemical and physiological traits of the bacterial isolates were determined to aid identification. Nitrate reduction, indole formation and expression of β-galactosidase activity were assayed. Growth at both 15° C. and 45° C., growth in the presence of increasing concentrations of NaCl up to 5.0% and protease activity on gelatin were determined. Growth characteristics of the strains in litmus milk were also assessed.
- Species Identification
- The API 50CHL (BioMerieux SA, France) system was used to tentatively identify the Lactobacillus species by their carbohydrate fermentation profiles. Overnight MRS cultures were harvested by centrifugation and resuspended in the suspension medium provided with the kit. API strips were inoculated and analysed (after 24 and 48 h) according to the manufacturers' instructions. Identity of the Lactobacillus sp. was confirmed by SDS-Polyacrylamide gel electrophoresis analysis (SDS-PAGE) of total cell protein.
- Enzyme Activity Profiles
- The API ZYM system (BioMerieux, France) was used for semi-quantitative measurement of constitutive enzymes produced by the Lactobacillus isolates. Bacterial cells from the late logarithmic growth phase were harvested by centrifugation at 14,000 g for 10 min. The pelleted cells were washed and resuspended in 50 mM phosphate buffer, pH 6.8 to the same optical density. The strips were inoculated in accordance with the manufacturers' instructions, incubated for 4 h at 37° C. and colour development recorded.
- Antibiotic Sensitivity Profiles
- Antibiotic sensitivity profiles of the isolates were determined using the ‘disc susceptibility’ assay. Cultures were grown up in the appropriate broth medium for 24-48 h, spread-plated (100 μl) onto agar media and discs containing known concentrations of the antibiotics were placed onto the agar. Strains were examined for antibiotic sensitivity after 1-2 days incubation at 37° under anaerobic conditions. Strains were considered sensitive if zones of inhibition of 1 mm or greater were seen.
- Plasmid Profile Analysis
- Plasmid profile analysis of ten Lactobacillus sp. was performed using the (Anderson, D. L. and McKay L. L., (1983)Appl. Env. Microbiol. 46, 549-552) lysis procedure with the following modifications. Bacterial cells were inoculated (4%) into 100 ml MRS broth supplemented with 40 mM DL-threonine and incubated for 4-5 h (mid-log phase). Cells, harvested by centrifugation, were used immediately for the plasmid DNA preparation. Before the lysis step, lysozyme (10 mg/ml) and mutanolysin (10 μg/ml) were added to the cell suspensions and incubated at 37° C. for 1 h and subsequently at 4° C. for 30 min. After the addition of 5 M NaCl, the lysates were put on ice for 30 min. The DNA was electrophoresed on 0.7% vertical agarose. gels in Tris-acetate buffer for 4-5 h at 100V.
- Isolation of Lactobacillus sp.
- Seven tissue sections taken from the human G.I.T. were screened for the presence of strains belonging to the Lactobacillus genus. There was some variation between tissue samples as follows. Samples A (ileum) and E (appendix) had the lowest counts with approximately 102 cells isolated per gram of tissue. In comparison, greater than 103 cfu/g tissue were recovered from the other samples. Similar numbers of bacteria were isolated during the ‘wash’ and ‘sample’ steps with slightly higher counts in the ‘sample’ solutions of F (ileum) and G (ileal-caecal). Of those screened for tightly-adhering bacteria (homogenised), C (ileal-caecal) was the only tissue section that gave significant counts.
- During the screening of some tissue sections, for example C and B, there was not a direct correlation between counts obtained during a dilution series. This would indicate that some growth factors, either blood or tissue derived, were being provided for the growth of the fastidious bacteria in the initial suspension which was subsequently diluted out.
- Strain Selection and Characterization
- Approximately fifteen hundred catalase negative bacterial isolates from different samples were chosen and characterised in terms of their Gram reaction, cell size and morphology, growth at 15° and 45° C. and fermentation end-products from glucose. Greater than sixty percent of the isolates tested were Gram positive, homofermentative cocci arranged either in tetrads, chains or bunches. Eighteen percent of the isolates were Gram negative rods and heterofermentative coccobacilli. The remaining isolates (twenty-two percent) were predominantly homofermentative coccobacilli. Thirty eight strains were characterised in more detail—13 isolates from G; 4 from F; 8 from D; 9 from C; 3 from B and 1 from E. All thirty eight isolates tested negative both for nitrate reduction and production of indole from tryptophan.
- Species Identification
- The API 50CHL allowed rapid identification of the Lactobacillus isolates.
- Seven of the isolates were very typical of thesalivarius species according to their carbohydrate fermentation profiles. All seven fermented fructose, glucose, mannose, sorbose and raffinose efficiently. None fermented amygdaline. There was some variability: four of the strains fermented ribose, two were negative for lactose utilisation and three isolates partially fermented rhamnose. These, however, are not uncommon traits of the salivarius sp. (Bergey's Manual). Three of the isolates possessed similiar fermentation profiles to Lactobacillus casei subsp. casei. They fermented ribose, galactose, glucose, fructose, arbutine, cellobiose, lactose, saccharose, tagatose and gluconate. However, none fermented gentibiose or turanose and one strain was negative for growth on sorbitol and amygdaline. The three isolates fermented glycerol which is a trait common to twenty percent of casei subsp. casei strains. Five isolates were tentatively classified in the plantarum/pentosus group. They were positive for fermentation of ribose, galactose, glucose, fructose, sorbitol, lactose, cellibiose and esculine. All but two fermented melezitose, four were positive for trehalose, two were positive for tagatose and one for gluconate. All fermented L-arabinose but only one fermented D-arabinose. None were able to grow on raffinose. Analysis of total cell protein of the Lactobacillus sp. by SDS-PAGE revealed two main species, salivarius and paracasei.
- A summary of the strain identification is included in Table 2. In Table 2 and in the following Tables 3-6 and the related description the prefix UCC has been omitted for the Lactobacillus strains.
TABLE 2 Identification of selected Lactobacillus strains by two different techniques Sugar fermentation Total cell protein Strain profiles (SDS-PAGE)* Lactobacillus sp. 1 L. salivarius L. salivarius subsp. salivarius 4333 L. salivarius L. salivarius subsp. salivarius 43310 L. salivarius L. salivarius subsp. salivarius 43321 L. salivarius L. salivarius subsp. salivarius 43324 L. salivarius L. salivarius subsp. salivarius 43332 L. casei subsp. casei L. paracasei subsp. paracasei 43336 L. casei subsp. casei ND 43338 L. plantarum L. paracasei subsp. paracasei 43348 L. pentosus L. salivarius subsp. salivarius 43361 ND L. salivarius subsp. salivarius 43362 L. plantarum L. paracasei subsp. paracasei 43364 L. casei subsp. casei L. paracasei subsp. paracasei 118 L. salivarius L. salivarius subsp. salivarius 4231 L. salivarius L. paracasei subsp. paracasei 42319 L. casei rhamnosus/ ND pentosus 42354 L. casei rhamnosus/ ND pentosus 42361 L. pentosus ND - Enzyme Activity Profiles
- Enzyme activity profiles for the seventeen Lactobacillus sp. tested were carried out and the results were as follows:
- None of the strains exhibited lipase, trypsin, α-chymotrypsin, β-glucuronidase, α-mannosidase or α-fucosidase activities and only weak β-glucosidase, N-acetyl-β-glucosaminidase activity was observed by three (43332, 43338, 43364) of the strains. All the strains tested were characterised by high acid phosphatase activity (means of 5.0) with phosphohydrolase and alkaline phosphatase activity being lower and more strain variable. Significant β-galactosidase activity was expressed by nine of the seventeen strains but little α-galactosidase activity was evident. Moderate to high levels of leucine, valine and cystine arylamidase activity was observed.
- Antibiotic Sensitivity Profiles
- Antibiotics of human clinical importance were used to ascertain the sensitivity profiles of selected lactobacilli. The lactobacilli tested were sensitive to ampicillin, amoxycillin, ceftaxime, ceftriaxone, ciprofloxacin, cephradine, rifampicin and chloramphenicol. They were also resistant to netilmicin, trimethoprim, nalidixic acid, amikacin, vancomycin and gentamicin. Variable sensitivity of the lactobacilli to teicoplanin and ceftizoxime was also observed.
- Source and Maintenance of Strains
- The Lactobacillus strains used were isolated as described in Example 1.
- Human Gastric Juice
- Human gastric juice was obtained from healthy subjects by aspiration through a nasogastric tube (Mercy Hospital, Cork, Ireland). It was immediately centrifuged at 13,000 g for 30 min to remove all solid particles, sterilised through 0.45 μm and 0.2 μm filters and divided into 40 ml aliquots which were stored at 4° C. and −20° C.
- The pH and pepsin activity of the samples were measured prior to experimental use. Pepsin activity was measured using the quantitative haemoglobin assay (Gautam, S. and de La Motte, R. S., (1989)Proteolytic enzymes, a practical approach.
Chapter 3. R. J. Beynon and J. S. Bond (eds.), IRL Press, Oxford University Press; (Dawson, R. M. (1969) In Data for Biochemical Research 138. R. M. Dawson, D. C. Elliot and K. M. Jones (eds.), Clarendon Press, Oxford). Briefly, aliquots of gastric juice (1 ml) were added to 5 ml of substrate (0.7 M urea, 0.4% (w/v) bovine haemoglobin (Sigma Chemical Co.), 0.25 M KCl-HCl buffer, pH 2.0) and incubated at 25° C. Samples were removed at 0, 2, 4, 6, 8, 10, 20 and 30 min intervals. Reactions were terminated by the addition of 5% trichloroacetic acid (TCA) and allowed to stand for 30 min without agitation. Assay mixtures were then filtered (Whatman, No. 113), centrifuged at 14,000 g for 15 min and absorbance at 280 nm was measured. One unit of pepsin enzyme activity was defined as the amount of enzyme required to cause an increase of 0.001 units of A280nm per minute at pH 2.0 measured as TCA-soluble products using haemoglobin as substrate. - Growth of lactobacilli at Low pH
- To determine whether growth of the Lactobacillus strains occurred at low pH values equivalent to those found in the stomach, overnight cultures were inoculated (1%) into fresh MRS broth adjusted to pH 4.0, 3.0, 2.0 and 1.0 using 1N HCl. At regular intervals aliquots (1.5 ml) were removed, optical density at 600 nm (OD600) was measured and colony forming units per ml (cfu/ml) calculated using the plate count method. Growth was monitored over a 24-48 h period.
- Survival of Strains in a Low pH Environment
- Survival of the strains at low pH in vitro was investigated using two assays:
- (a) Cells were harvested from fresh overnight cultures, washed twice in phosphate buffer (pH 6.5) and resuspended in MRS broth adjusted to pH 3.5, 3.0, 2.5 and 2.0 (with 1N HCl) to a final concentration of approximately 108 cfu/ml for the lactobacilli. Cells were incubated at 37° C. and survival measured at intervals of 5, 30, 60 and 120 min using the plate count method.
- (b) The Lactobacillus strains were propagated in buffered MRS broth (pH 6.0) daily for a 5 day period. The cells were harvested, washed and resuspended in pH adjusted MRS broth and survival measured over a 2 h period using the plate count method.
- Survival of Microorganisms in Human Gastric Juice
- To determine the ability of the lactobacilli to survive passage through the stomach, an ex-vivo study was performed using human gastric juice. Cells from fresh overnight cultures were harvested, washed twice in buffer (pH 6.5) and resuspended in human gastric juice to a final concentration of 106-108 cfu/ml, depending on the strain. Survival was monitored over a 30-60 min incubation period at 37° C. The experiment was performed using gastric juice at pH˜1.2 (unadjusted) and pH 2.0 and 2.5 (adjusted using 1N NaOH).
- Growth of Lactobacillus sp. at Low pH
- The Lactobacillus strains (of human origin) grew normally at pH 6.8 and pH 4.5 reaching stationary phase after 8 h with a doubling time of 80-100 min. At pH 3.5 growth was restricted with doubling times increasing to 6-8 h. No growth was observed at pH 2.5 or lower, therefore, survival of the strains at low pH was examined.
- Survival of Lactobacillus sp. at Low pH
- HCl-Adjusted Medium:
- The Lactobacillus strains were generally resistant to pH values 3.5, 3.0 and 2.5. At pH 2.0, strain variation became apparent (see FIG. 1). The Lactobacillus strains of human origin survived with little log reduction for 1 h, however,
Lactobacillus 118 had decreased by 2-4 log after 2 h incubation (see FIG. 2). - Human Gastric Juice:
- To determine the ability of Lactobacillus strains to survive conditions encountered in the human stomach, viability of the strains was tested in human gastric juice at pH 1.2 and pH 2.5. Gastric juice adjusted to pH 2.5 was used to determine if factors other than pH are important in the inhibition of these strains by gastric juice. The strains according to the invention were recovered after 30 min incubation in gastric juice, pH 1.2, though at a reduced level. In gastric juice, pH 2.5, viability was approximately 100% in most cases, indicating that pH is the major inhibitory factor of gastric juice.
- Inducible Acid Tolerance in Lactobacillus sp.
- To determine strain survival at low pH after growth in a buffered carrier medium, the strains were grown continuously for one week at pH 7.0 and then challenged in MRS adjusted to pH 2.0-3.5 using 1N HCl. The Lactobacillus strains were resistant to pH values 3.5 and 3.0. At lower pH a distinct decrease in cell viability was observed. At pH 2.0 a rapid decline in cell number was recorded for example after 1 h incubation resulting in Lactobacillus sp. 118 and eight other strains not being recovered (see FIG. 3). After a further incubation of 1 h, five strains were recovered and these at levels of approximately 105 cfu/ml.
- It was observed in this study that prior growth of the Lactobacillus strains in buffered medium rendered them much more sensitive, in vitro, to low pH. Viable cells were not recovered after 30-60 min incubation at pH 2.0. When compared with survival of cells grown in unbuffered medium, it is clear that these strains possess the ability to adapt to a low pH environment after prior growth in pH environments of 4.0-4.5.
- Lactobacillus strains used were isolated as described in Example 1.
- Growth of Cultures in the Presence of Bovine and Porcine Bile
- Fresh cultures were streaked onto MRS/TPY agar plates supplemented with bovine bile (B-8381, Sigma Chemical Co. Ltd., Poole) at concentrations of 0.3, 1.0, 1.5, 5.0 and 7.5% (w/v) and porcine bile (B-8631, Sigma Chemical Co. Ltd., Poole) at concentrations of 0.3, 0.5, 1.0, 1.5, 5.0 and 7.5% (w/v). Plates were incubated at 37° C. under anaerobic conditions and growth was recorded after 24-48 h.
- Growth of Cultures in the Presence of Human Bile
- Bile samples, isolated from several human gall-bladders, were stored at −80° C. before use. For experimental work, bile samples were thawed, pooled and sterilised at 80° C. for 10 min. Bile acid composition of human bile was determined using reverse-phase HPLC in combination with a pulsed amperometric detector according to the method of (Dekker, R. R. et al., (1991)Chromatographia 31 (11/12), 255-256). Human bile was added to MRS/TPY agar medium at a concentration of 0.3% (v/v). Freshly streaked cultures were examined for growth after 24 and 48 h.
- Growth in the Presence of Individual Conjugated and Deconjugated Bile Acids
- Human gall-bladder bile possesses a bile acid concentration of 50-100 mM and dilution in the small intestine lowers this concentration to 5-10 mM (Hofmann, A. F., et al., (1983)J. Clin. Invest. 71, 1003-1022). Furthermore, under physiological conditions, bile acids are found as sodium salts. Therefore, cultures were screened for growth on MRS/TPY agar plates containing the sodium salt of each of the following bile acids (Sigma Chemical Co. Ltd., Poole): (a) conjugated form: taurocholic acid (TCA); glycocholic acid (GCA); taurodeoxycholic acid (TDCA); glycodeoxycholic acid (GDCA); taurochenodeoxycholic acid (TCDCA) and glycochenodeoxycholic acid (GCDCA); (b) deconjugated form: lithocholic acid (LCA); chenodeoxycholic acid (CDCA); deoxycholic acid (DCA) and cholic acid (CA). For each bile acid concentrations of 1, 3 and 5 mM were used. Growth was recorded after 24 and 48 h anaerobic incubation.
- Detection of Bile Acid Deconjugation Activity
- Both a qualitative (agar plate) and a quantitative (HPLC) assay were used to determine deconjugation activity.
- Plate assay: All the cultures were streaked on MRS/TPY agar plates supplemented with (a) 0.3% (w/v) porcine bile, (b) 3 mM TDCA or (c) 3 mM GDCA. Deconjugation was observed as an opaque precipitate surrounding the colonies (Dashkevicz, M. P., et al. (1989)Appl. Env. Microbiol. 55(1), 11-16).
- High Performance Liquid Chromatography:
- Analysis of in vitro deconjugation of human bile was performed using HPLC (Dekker, R. R. et al., (1991) supra). Briefly, overnight cultures were inoculated (5%) into MRS/TPY broth supplemented with 0.3% (v/v) human bile and were incubated anaerobically at 37° C. At various time intervals over a 24 h period, samples (1 ml) were removed and centrifuged at 14,000 rpm for 10 min. Undiluted cell-free supernatant (30 μl) was then analysed by HPLC.
- Isolation of Lactobacillus Variants with Increased Bile Acid Resistance
- A single Lactobacillus colony was inoculated into MRS broth containing 0.3% porcine bile and incubated overnight. The culture was centrifuged at 14,000 rpm for 7 min, washed and resuspended in one quarter strength Ringers' solution. One hundred microlitres of a 10−3 dilution was spread-plated onto MRS agar plates consisting of a porcine bile gradient from 0.3 to 0.5%. The plates were incubated for 2 days at 37° C. Isolated colonies were picked from the agar sector containing 0.5% porcine bile, restreaked onto MRS supplemented with 0.5% porcine bile and incubated overnight. A number of colonies were then resuspended in one quarter strength Ringers' solution, diluted to 10−3 and plated onto gradient plates of increasing concentrations of porcine bile (0.5/1.0%, 1.0/1.5%, 1.5/2.0%, 2.0/2.5% and 2.5/3.0%). Colony morphology, Gram stains, wet mounts and catalase tests were performed on the colonies with increased resistance.
- Resistance to Bile (Bovine, Porcine and Human)
- All seventeen Lactobacillus strains tested were capable of growth (bile acid resistance) on three sources of bile used. It was observed that resistance to bovine bile was much higher than to porcine bile. Lactobacillus strains were resistant to concentrations up to and including 5.0% bovine bile and fourteen of the seventeen strains grew at 7.5%.
- Porcine bile was more inhibitory to all strains as shown in Table 3.
TABLE 3 Growth of bacterial isolate in the presence of porcine bile % (w/v) PORCINE BILE STRAIN 0.0 0.3 0.5 1.0 1.5 5.0 7.5 Lactobacillus sp. 1 + + − − − − − 4333 + + − − − − − 43310 + + − − − − − 43321 + + − − − − − 43324 + + − − − − − 43332 + + + + − − − 43336 + + − − − − − 43338 + + − − − − − 43348 + + − − − − − 43361 + + + + + + − 43362 + + − − − − − 43364 + + − − − − − 118 + + + + − − − 4231 + + − − − − − 42319 + + + + + + + 42354 + + + + + + + 42361 + + + + + + + - Concentrations of 0.5% and higher inhibited the growth of ten of the seventeen Lactobacillus strains, whereas Lactobacillus sp. 42319, 42354 and 42361 grew to confluence at 7.5%.
- Regardless of their bile resistance profiles in the presence of both bovine and procine bile, the Lactobacillus strains grew to confluence at the physiological concentration of 0.3% (v/v) human bile.
- Resistance to Individual Conjugated and Deconjugated Bile Acids
- The Lactobacillus strains, when analysed specifically for their resistance to individual bile acids, grew well in the presence of taurine conjugated bile acids but growth in the presence of glycine conjugated bile acids was variable. Lactobacillus isolates grew to confluence on agar medium containing up to and including 5 mM of taurine conjugates TCA, TDCA and TCDCA. Of the glycine conjugates tested, GCDCA was the most inhibitory, with only four of the Lactobacillus sp. being able to grow at concentrations of 3 mM and 5 mM. GDCA was less inhibitory and GCA was the least inhibitory of the three glycine conjugates as shown in Table 4.
TABLE 4 Growth of bacterial isolates in the presence of glycine-conjugated bile acids BILE ACIDS (mM) GCDCA GDCA GCA STRAIN 0 1 3 5 0 1 3 5 0 1 3 5 Lactobacillus sp. 1 + + − − + + − − + + + + 4333 + + − − + + + + + + + + 43310 + + − − + + − − + + + + 43321 + + − − + + − − + + + + 43324 + + − − + + − − + + + + 43332 + + − − + + − − + + + + 43336 + + − − + + + − + + + + 43338 + + − − + + + − + + + + 43348 + + − − + + − − + + + + 43361 + + + + + + + + + + + + 43362 + + − − + + + − + + + + 43364 + + − − + + + − + + + + 118 + + − − + + + − + + + + 4231 + + − − + + + − + + + + 42319 + + + + + + + + + + + + 42354 + + + + + + + + + + + + 42361 + + + + + + + + + + + + - All strains grew on agar medium supplemented with 5 mM GCA, however, growth on GDCA was variable.
- Growth in the presence of deconjugated bile acids was also tested. All strains were resistant to concentrations of 5 mM LCA. Fifteen of the seventeen Lactobacillus strains tested grew in concentrations of up to and including 5 mM DCA. Two strains, Lactobacillus sp. 1 and 43348, were sensitive to low concentrations of DCA (1 mM). Growth in the presence of CA was variable as shown in Table 5.
TABLE 5 Growth of bacterial isolates in the presence of unconjugated cholic acid (CA) CHOLIC ACID (mM) STRAIN 0 1 3 5 Lactobacillus sp. 1 + − − − 4333 + − − − 43310 + + − − 43321 + − − − 43324 + + − − 43332 + + − − 43336 + + − − 43338 + + + + 43348 + − − − 43361 + + + + 43362 + + + − 43364 + + + + 118 + + + − 4231 + + − − 42319 + + + + 42354 + + + + 42361 + + + + - Only eight Lactobacillus strains were capable of growing on a concentration of 3 mM CA. Growth of the seventeen strains was not observed in the presence of 1 mM CDCA.
- Deconjugation Activity of Lactobacillus sp.
- From the growth studies it was observed that some of the strains possessed bile salt deconjugating activity and further investigation identified and three seventeen Lactobacillus strains (43361, 42319 and 42361) which were capable of deconjugating bile acids. This was demonstrated on agar medium supplemented with 0.3% porcine bile, TDCA (3 mM) and GDCA (3 mM). In all cases, deconjugation manifested itself as an opaque zone of precipitated deconjugated bile acid surrounding active colonies (Dashkevicz, M. P. and Feighner, S. D., (1989)Appl. Env Microbiol. 55(1), 11-16).
- Bile acid deconjugation activity, observed on agar plates, was confirmed using human bile and HPLC analysis of breakdown products. Only conjugated bile acids were detected in the bile sample.
- Induction of Bile Acid Resistance
- A method was devised for the isolation of Lactobacillus strains with increased bile acid resistance. Two Lactobacillus strains (4333 and 43310) were chosen which were initially unable to grow in the presence of 0.5% porcine bile but which could grow at a concentration of 0.3% (see. Table 3 above). Following continuous sub-culturing in the presence of increasing concentrations of porcine bile (0.3% to 3.0%), the resistance of
strains 4333 and 43310 increased. Strains regularly sub-cultured on MRS agar maintained their induced bile resistance when restreaked onto MRS agar containing 3.0% porcine bile. Furthermore, induced bile resistant strains were subsequently able to deconjugate porcine bile. - With increasing concentrations of porcine bile, changes in colony morphology were observed with both strains tested. The colonies were irregular, flat to umbonate, and appeared grey and opaque in the presence of bile. However, when restreaked onto MRS agar, the colonies regained their original, smooth, creamy, convex, glistening appearance. (When viewed under the microscope both colony variants appeared as short rods, singly or in pairs). After prolonged sub-culturing in the absence of bile both strains still deconjugated and maintained resistance to high levels of porcine bile.
- Growth and Maintenance of Cultures
- The microorganisms screened for antimicrobial production were the seventeen strains listed in Table 3 and were isolated from the human intestinal tract as described in Example 1. All strains belonged to the UCC culture collection
- Cultures were maintained as frozen stocks at −20° C. in the appropriate growth medium and 40% glycerol. Lactobacilli were routinely cultured in deMann Rogosa Sharpe (MRS) medium at 37° C. under strict anaerobic conditions (BBL Gas Jars using the Merck Anaerocult A Gas Pak system).
- The indicator microorganisms used in this Example, many of which are wildtype strains isolated in the Mercy Hospital, Cork, Ireland, were propagated in the following medium under the following growth conditions: Staphylococcus (37° C., aerobic), Bacillus (37° C., aerobic), Pseudomonas (30° C., aerobic),Escherichia coli (37° C., anaerobic), Salmonella (37° C., anaerobic) and Listeria (30° C., aerobic) in Tryptone Soya broth/agar supplemented with 0.6% yeast extract (TSAYE, Oxoid), Campylobacter (37° C., anaerobic), Bacteroides (37° C., anaerobic), Helicobacter (37° C., anaerobic), Proteus (37° C., anaerobic), Haemophilus (37° C., anaerobic) and Pneumococcus (37° C., anaerobic) on Blood agar medium, Candida (37° C., aerobic) in YPD (Yeast (1%), Peptone (2%) and Dextrose (2%)) medium, Clostridium (37° C., anaerobic) in Reinforced Clostridial medium (RCM, Oxoid), Lactococcus (30° C., aerobic) in M17 medium (Oxoid), Streptococcus (37° C., anaerobic) in Todd Hewitt Medium (Oxoid) and Enterococcus (37° C., anaerobic) species in Brain Heart Infusion medium (BHI, Merck). All strains were inoculated into fresh growth medium and grown overnight before being used in experiments. Agar sloppies (overlays) and plates were prepared by adding 0.7% (w/v) and 1.5% (w/v) agar to the broth medium, respectively.
- Detection of Antimicrobial Activity
- Antimicrobial activity of the above strains was detected using the deferred method (Tagg J. R., et al. (1976)
Bacteriol. Rev 40, 722-756). Indicators used in the initial screening were L. innocua, L. fermentum KLD, P. flourescens and E. coli V517. Briefly, the lactobacilli (MRS) were incubated for 12-16 h. Ten-fold serial dilutions were spread-plated (100 μl) onto MRS agar medium. After overnight incubation, plates with distinct colonies were overlayed with the indicator bacterium. The indicator lawn was prepared by inoculating a molten overlay with 2% (v/v) of an overnight indicator culture which was poured over the surface of the inoculated MRS plates. The plates were re-incubated overnight under conditions suitable for growth of the indicator bacterium. Indicator cultures with inhibition zones greater than 1 mm in radius were considered sensitive to the test bacterium. - This procedure was repeated with the supplementation of all agar media with 2% β-glycerophosphate buffer (Sigma Chemicals, Poole) and catalase (100 Units/ml; Sigma Chemicals, Poole), to eliminate antagonistic activity due to acid and hydrogen peroxide production, respectively. Inhibition due to bacteriophage activity was excluded by flipping the inoculated MRS agar plates upside down and overlaying with the indicator. Bacteriophage can not diffuse through agar.
- Detection of Antimicrobial Activity in the Cell-Free Supernatant
- To determine if antimicrobial activity is secretory in nature, lactobacilli (MRS) were grown in broth for 12-16 h, aliquots of culture (500 μl) were filter-sterilised (0.45 μm) and the cell-free supernatant was assayed for antimicrobial activity against the same four indicator strains. Activity of the cell-free supernatant was determined by a modification of the critical dilution method generally used for assay of bacteriocins (Mayr-Harting, A., et al., (1972)Methods in Microbiology Vol. 7A, 315-422). Two-fold serial dilutions were spotted (5 μl) onto freshly seeded lawns of L. innocua and L. fermentum KLD and the plates incubated appropriately. The titre was defined as the reciprocal of the highest dilution of inhibitor demonstrating complete inhibition of the indicator lawn and was expressed as activity units (AU) per millilitre (ml).
- Ammonium Sulphate Precipitation of Antimicrobial Activity
- The antimicrobial-producing strains,
L. salivarius - Inhibitory Host Spectra
- The inhibitory spectra of lactobacilli were determined by the method of Tagg, J. R. et al. (1976) as described above. Cell-free supernatant (CFS) and ammonium sulphate precipitated solution (APS) were also assayed for inhibitory activity against a wide range of Gram positive and Gram negative microorganisms. Overlays of each indicator were prepared on agar plates and allowed to dry. Spots (5μl) of CFS and APS were placed on the seeded plates, allowed to dry and plates incubated overnight. The agar well-diffusion method was also employed for the inhibition of Helicobacter , Proteus, Bacteroides and Campylobacter sp. Agar plates were either overlayed or swabbed with the indicator organism and allowed to dry. Wells (4 mm) were made in the agar plates and CFS (30-40 μl) was placed in the wells and allowed to diffuse through the agar for 20-40 min at room temperature prior to incubation for 24-48 h after which inhibitory zones were measured.
- Sensitivity of Antimicrobials to Proteolytic Enzymes
- Aliquots of CFS containing antimicrobial activity from individual producing strains were assayed for their sensitivity to proteolytic enzymes. Proteinase K (50 mg/ml, 50 mM KH2PO4, pH 7.5) and pronase E (50 mg/ml, 50 mM KH2PO4, pH 7.5) were individually incubated for 1 h at 37° C. with CFS at 3:1 ratio. Both enzyme-treated and untreated CFS were spotted (5 μl) onto freshly seeded indicator overlays agar and incubated appropriately.
- Production of Antimicrobial Activity in Human Bile
-
Cultures - Detection of Antimicrobial Activity
- The seventeen lactobacilli were screened for inhibitory activity usingLs. innocua, L. fermentum KLD, P. fluorescens and E. coli as indicator microorganisms. When the test strains were inoculated on unbuffered MRS, inhibition of the four indicators was observed. Zones ranging in size from 1 mm to 5 mm were measured. Inhibition of Ls. innocua by the lactobacilli produced the largest zones.
- Inhibition was not due to hydrogen peroxide since incorporation of catalase to MRS plates during the screening did not affect antimicrobial activity. Similarly, bacteriophage activity was excluded as described above. When the lactobacilli were inoculated onto buffered MRS, very little inhibition towards the indicators was observed. There were two exceptions,
L. salivarius - Characterisation of Antimicrobial Activity
- The antimicrobial activity of Lactobacillus sp. 1 and 118 was demonstrated to be secreted into the cell-free supernatant after 8 h of growth in MRS broth when assayed againstLs. innocua and
B. coagulans 1761. CFS of 118 also exhibited inhibition towards P. fluorescens but this indicator was less sensitive than the previous two. Inhibition of E. coli by either ABP1 or ABP118 was not observed. Titres of up to 2000 AU/ml and 1000 AU/ml (using Ls. innocua and L. fermentum KLD, respectively) were measured. The inhibitory activities ofL. salivarius - Inhibitory Host Spectra
- The lactobacilli were seen to inhibit a wide range of both Gram positive and Gram negative indicator microorganisms in both buffered and unbuffered media. Little inhibitory activity was observed towards lactic acid bacteria, such as Streptococcus and other lactobacilli. The inhibitory spectra of
L. salivarius TABLE 6 Inhibitory spectra of ABP1 and ABP118, produced by L. salivarius 1 and 118, respectively Indicator strains ABP118 ABP1 Lactobacillus salivarius 1 − − L. salivarius 118− − Enterococcus faecalis + + E. faecium + + Staphylococcus aureus 1505 + + St. aureus 1551 + + St. aureus 1522 + + St. aureus 1963 + + St. aureus 2044 +/− +/− St. aureus 771 + + St. aureus 6511 − +/− St. aureus MH + − St. aureus 148 (methicillin + − resistant) St. carnosus + + Bacillus subtilus DW + + B. cereus DW + + B. cereus NCDO 577 + − B. thuringensis 1146 − + B. megaterium 1773 + + B. coagulans 1761+ + Clostridium tyrobutyricum 1756 +/− +/− C. tyrobutyricum 885A +/− +/− C. tyrobutyricum 1757 +/− +/− C. tyrobutyricum 1729 +/− +/− C. butyricum 7423 +/− +/− Pneumococcus sp. 788 +/− +/− Pneumococcus sp. 904 +/− +/− Haemophilus sp. − − Pseudomonas fluorescens + P. fragi + − Escherichia coli 1266 − − E. coli V517 − − E. coli − − Enterobacter sp. 736 − − Salmonella typhimurium LT2 − − S. typhimurium − − S. enteriditis − − Helicobacter pylori Pu25 − − H. pylori Pu35 + − H. pylori Pu37 − − Campylobacter sp. − − Bacteroides sp. 28644-1 + nd Bacteroides sp. 28644-2 + nd Proteus sp. 776 − − Proteus sp. 778 − − Proteus sp. 889 − − Listeria monocytogenes + + Ls. innocua + + - Growth and Maintenance of Cultures
-
Lactobacillus salivarius 118 was isolated, identified and cultured from the human intestinal tract as described in Example 1. - The indicator microorganisms used in this Example were propagated in Tryptone Soya broth supplemented with 0.6% yeast extract (TSAYE, Oxoid) under the following growth conditions, Bacillus (37° C., aerobic),Escherichia coli (37° C, anaerobic), Salmonella (37° C., anaerobic) and Listeria (30° C., aerobic). All strains were inoculated into fresh growth medium and grown overnight before being used in experiments. Agar sloppies (overlays) and plates were prepared by adding 0.7% (w/v) and 1.5% (w/v) agar to the broth medium, respectively.
- Detection of Antimicrobial Activity
-
L. salivarius 118 was grown for 12-16 h in MRS broth and the culture centrifuged at 14,000 g for 10 min. Cell-free supernatant (CFS) was spotted (5-10 μl) onto freshly seeded lawns of Listeria innocua andBacillus coagulans 1761. Zones of inhibition were measured. - Activity of the CFS was assayed for by a modification of the critical dilution method generally used for assay of bacteriocins (Mayr-Harting et al., (1972) supra). Serial dilutions were spotted (5 μl) onto freshly seeded lawns ofLs. innocua and
B. coagulans 1761 and the plates incubated appropriately. The titre was defined as the reciprocal of the highest dilution of inhibitor demonstrating complete inhibition of the indicator lawn and was expressed as activity units (AU) per millilitre (ml). - Ammonium Sulphate Precipitation of the Cell-Free Supernatant Containing ABP118
-
L. salivarius 118 was grown in broth (800 ml) under anaerobic conditions at 37° C. and cells were harvested after 6-8 h incubation. The supernatant was concentrated using 40% ammonium sulphate for 1 h at 4° C. with constant agitation, held at 4° C. overnight and then centrifuged at 13,000 g for 30 min. The pellet and the pellicle (the layer at the top of the supernatant) were collected and dissolved in a small volume of phosphate buffer, pH 6.5. The solutions were dialyzed against 5 1 of phosphate buffer, pH 6.5, for 24 h at 4° C. with 2-3 changes of buffer. Solutions were then filter sterilised, assayed for antimicrobial activity and stored at 4° C. This was used in the following experiments unless otherwise stated. - Factors Influencing Growth ofL. salivarius 118 and Production of ABP118
- pH:
-
L. salivarius 118 was grown up overnight in MRS broth (50 ml) at 37° C. and then inoculated (2%) into MRS broth (1.5 l) in a fermentation vessel (Model 502D; L. H. Fermentation, Stoke Poges, Bucks.) which was connected to an automatic pH controller, at 37° C., with gentle agitation (200 rpm) and continuously flushed with 5% CO2. The following pH conditions were imposed in four different experiments: (1) pH 5.5; (2) pH 5.0; (3) pH 4.5 and (4) pH 4.0 and pH was maintained using 8% ammonium hydroxide solution during the experiment. At regular intervals pH, OD600, bacterial counts (cfu/ml) and antimicrobial activity (AU/ml) were recorded over a 24 h period. - Growth Medium:
- Various laboratory media were tested for their ability to support both the growth ofL. salivarius 118 and the production of ABP118. These included MRS, Brain Heart Infusion (BHI), GM17 and Tryptone Soya broth supplemented with 0.6% yeast extract (TSBYE). The effects of the elimination of media constituents from MRS broth on growth and antimicrobial production was also evaluated. The ingredients eliminated included, a)
Tween 80, b) Peptone, c) Yeast extract, d) Beef extract, e)Tween 80 and beef extract and f)Tween 80, beef extract and peptone. - Growth and antimicrobial production was also monitored in, 13.5% skim milk; 13.5% skim milk supplemented with 0.6% yeast extract; 13.5% skim milk supplemented with 2% glucose and 13.5% skim milk supplemented with 2% glucose and 0.6% yeast extract, and in MRS broth supplemented with 0.3% human bile (obtained from human gall-bladder and sterilised at 80° C. for 10 mins). At regular intervals, pH, OD600, bacterial counts and antimicrobial activity were recorded. All growth curves were carried out at 37° C. under anaerobic conditions.
- pH and Temperature Stability of ABP118
- ABP118 was tested for its stability in both alkaline and acidic conditions. pH of the active CFS was adjusted from 1 to 10 using 1N NaOH and HCl. Solutions were filter-sterilised and after incubation for 1 h at room temperature, activity was calculated before and after adjustment usingLs. innocua as the indicator. The pH-adjusted solutions were then readjusted to
pH 7 using 1N NaOH and HCl and again incubated for 1 h at room temperature and assayed for AU/ml. Controls used were MRS broth adjusted to the same pH values. - To determine the temperature stability of ABP118, aliquots (10 ml) were incubated at various temperatures for different time periods and activity was calculated before and after incubation, using the indicatorLs. innocua.
- Sensitivity of ABP118 to the Actions of Enzymes, Detergents and Organic Solvents
- To determine the nature and stability of the antimicrobial activity, ABP118 was incubated with the following enzymes (in a 3 to 1 ratio) for 30-60 min and assayed for antimicrobial activity: proteinase K (50 mg/ml, 50 mM KH2PO4, pH 7.5); pronase E (50 mg/ml, 50 mM KH2PO4, pH 7.5); trypsin (50 mg/ml, 67 mM Na2PO4, pH 7.6); α-chymotrypsin (50 mg/ml. 80 mM Tris, pH 7.8); α-amylase (50 mg/ml, 20 mM Na2PO4, pH 6.9); protease-free lipase (50 mg/ml); ficin (10 mM KH2PO4, pH 7.0); catalase (50,000 U/ml dH2O); lysozyme (10 mg/ml, 25 mM Tris-HCl, pH 8.0); alkaline phosphatase (80 mM Tris-HCl, pH 8.0); pepsin (10 mM HCl); phospholipase C (10 mM KH2PO4, pH 7.0) and papain (10 mM KH2PO4, pH 7.0). Aliquots (5 μl) of each of these solutions were spotted onto plates already seeded with Ls. innocua and
B. coagulans 1761. Controls included buffer and enzyme, and ABP118. - ABP118 was also treated with a number of solvents and detergents for 1-2 h at 37° C. The solvents used were, 5% β-mercaptoethanol; 10% chloroform; 10% acetone; 10% isopropanol; 25% ethanol; 50% acetonitrile; 10% butanol and 50% dichloromethane. The detergents used included, Tween 80 (1%), Tween 20 (1%), Triton X-100 (1%), N-laurylsarcosine (1%) and SDS (0.1% and 1%). After incubation the solutions were either dialyzed, vaccum-, or freeze-dried and assayed for activity.
- Enzymatic Activity of ABP118
- ABP118 was applied to the ZYM kit (BioMerieux, France) which is used to assay for constitutive enzyme activity (see Example 1 above). To assay for haemolytic and proteolytic activity, ABP118 was spotted (10 μl) on blood agar and skim milk agar plates, respectively. Reactions were recorded after 24 h and 48 h incubation at 37° C.
- Determination of Molecular Size of ABP118 by Ultrafiltration
- The size of ABP118 was estimated from the cell-free supernatant (CFS) and ammonium sulphate precipitated solution (APS; see Example 4 above) of a
L. salivarius 118 culture. Aliquots were ultrafiltered through various membranes (Amicon Inc., MA., USA) including 100-, 30-, 10- and 3 kDa molecular exclusion sizes. Bacteriocin activity was determined in retained and flowthrough fractions. - Isolation of Variants Deficient in ABP118 Production
- MRS broth (100 ml) inoculated (2%) with
L. salivarius 118 was incubated at temperatures above that allowing optimal growth (40°, 42° and 45° C.). After 36-48 h growth, broths were serially diluted and spread-plated (100 μl) onto MRS agar. Colonies were then replicaplated onto MRS agar and MRS agar supplemented with 2% 3-glycerophosphate buffer. Plates were overlayed with sensitive indicator (B. coagulans 1761) and non-inhibiting colonies were streaked out for purity and stocked in 40% glycerol at −20° C. Growth rates of strains and carbohydrate fermentation profiles (API 50CHL) were recorded and compared to that of thewildtype L. salivarius 118. - Co-Culturing Studies
- Associative growth ofL. salivarius 118 and Salmonella (S. typhimurium and S. enteriditis) was studied in modified MRS medium (without sodium acetate). Indicator and producer strains were inoculated in 1:1 ratio. As a control, strains were also grown singly in the same medium. Inoculated media were incubated anaerobically at 37° C. Samples were taken at regular intervals to determine cell growth (cfu/ml). Salmonella-Shigella (Oxoid) and MRS (Oxoid) medium were used for the selective enumeration of Salmonella and Lactobacillus, respectively. Tryptone soya agar supplemented with 0.6% yeast extract (TSAYE) was used to obtain total plate counts. Salmonella were also co-cultured 1:1 with a non-ABP118-producing variant of the
wildtype L. salivarius 118. - Nature of the Antimicrobial Compound ABP118
- The inhibitor, ABP118, is protein in nature as it is neutralised by protease enzymes such as pronase E, trypsin and pepsin as shown in Tables 7 and 8 and is also actively secreted in the supernatant.
TABLE 7 Sensitivity of ABP118 to proteolytic and non-proteolytic enzymes Pronase E + Proteinase K + Trypsin + α-chymotrypsin + Ficin + Papain + Pepsin + Lipase (protease-free) − Catalase − Alkaline phosphatase − Phospholipase C − Lipoprotein lipase − -
TABLE 8 Effect of protease treatment on ABP118 activity Activity of ABP118 Treatment (AU/ml) ABP118 (no treatment) 2000 ABP118 + proteinase K at 37° C. × 30 min 0 ABP118 at 100° C. × 15 min 2000 ABP118 + [proteinase K at 100° C. × 15 min] 2000 at 37° C. × 30 min [ABP118 + proteinase K] at 100° C. × 15 min 2000 ([ABP118 + proteinase K] at 37° C. × 30 min) 0 at 100° C. × 15 min - Protease eliminated antimicrobial activity which was irretrievable after inactivation of the protease. ABP118 does not appear to have a lipid component based on the fact that lipase had no effect on activity (see Table 7). The compound was active in pH range 1-10 with no reduction in activity (againstLs. innocua) observed. It is a heat stable protein retaining 100% activity for at least 1 h at 100° C. and with only a 50% loss following severe heat treatment by autoclaving as shown in Table 9.
TABLE 9 Temperature stability profile of ABP118 Activity of ABP118 % Reduction of Treatment (AU/ml) ABP118 activity Untreated 2000 0 121° C. × 15 min 1000 50 100° C. × 1 h 2000 0 100° C. × 2 h 500 75 63° C. × 30 min 2000 0 60° C. × 1 h 2000 0 60° C. × 2 h 2000 0 37° C. × 1 week 500 75 30° C. × 1 week 1000 50 15° C. × 1 week 2000 0 4° C. × 4 months 2000 0 - The inhibitor ABP118 was also very stable when stored at 4° C. for 4 months with no loss in activity. Treatment of the compound with a number of organic solvents and detergents did not result in decreased activity as shown in Table 10.
TABLE 10 Stability of ABP118 in organic solvents and detergents Activity of ABP118 Treatment (AU/ml) Untreated 2000 Organic solvents Chloroform (10%) 2000 Acetone (10%) 2000 Isopropanol (10%) 2000 Ethanol (25%) 2000 Acetonitrile (50%) 2000 Butanol (10%) 2000 Dichloromethane (50%) 2000 β-mercaptoethanol (5%) 2000 Detergents Tween 80 (Trade Mark) (1%) 2000 Tween 20 (Trade Mark) (1%) 2000 Triton X (Trade Mark)-100 (1%) 2000 N-laurylsarcosine (1%) 2000 SDS (0.1%) 2000 SDS (1.0%) 1500 - When
ABP 118 was spotted on skim milk agar, no proteolysis was observed over a 24 h incubation period at 37° C. or at room temperature. Reactions on blood agar (rabbit and horse) were less conclusive. Though small zones of lysis were recorded, small zones of lysis were also observed when concentrated MRS broth was spotted on the blood agar plates. The ZYM kit, which assays for a wide range of enzymatic activity including esterase and lipase activity revealed no obvious enzymatic activity for ABP118. Ultrafiltration of culture supernatant and partially-purified ABP118 showed that the majority of activity was present in the retentate with the 100-kDa cutoff membrane and all activity was retained on the 30-kDa cutoff membrane. - Kinetics of ABP118 Production
- The production of ABP118 was dependent on the phase of growth. The kinetics of growth and antimicrobial production by
L. salivarius 118 is illustrated in FIG. 4. Production of ABP118 was maximal during the logarithmic phase with a reduction in ABP118 concentration during the stationary phase. Maximum concentration of ABP118 activity was found when pH was controlled at pH 5.5 with up to 4000 AU/ml being produced after 3-4 h when biomass was quite high. At pH 4.0 growth of the culture was reduced and ABP118 was not detected. These studies indicate that ABP118 is produced only by growing and not by non-growing cells. - Of the four laboratory media tested, MRS and BHI were the two most suitable for support of production of large concentrations of ABP118. To determine if a less complex medium would still support production of ABP118, the effect of
Tween 80, yeast extract and peptone sources was assayed. Results show that in the absence of any one of these, the concentration of ABP118 reached only 50% that of concentration produced in MRS broth. However, ABP118 activity remained more stable in the medium lacking yeast extract than in any other media tested. - The ability of a skim milk-based medium to act as a suitable carrier to support the growth ofL. salivarius 118 and production of ABP118 was investigated. Growth in skim milk, skim milk plus yeast extract, and skim milk plus glucose was quite poor. The pH did not go lower than 5.7 after 12 h incubation and little if any ABP118 activity was detected. However, when
L. salivarius 118 was grown in skim milk plus yeast extract plus glucose, pH reached a value of 4.4 and 3.87 after 12 and 24 h incubation, respectively. ABP118 activity was detected after 2 h at low levels and the majority of ABP118 (10,000 AU/ml against B. coagulans 1761) was produced by late-log to early-stationary phase of growth. It was also observed that the milk was beginning to clot after 10 h incubation. - The growth rate ofL. salivarius 118 in 0.3% human bile was equivalent to the growth rate in MRS broth. However, only one third of the concentration of ABP118 was produced.
- Detection of Antimicrobial Activity
- Spot Assay:
-
L. salivarius 118 was grown in MRS broth and the culture centrifuged at 14,000 g for 10 min. Cell-free supernatant (CFS) was spotted (5-10 μl) onto freshly seeded lawns of indicator, incubated and zones of inhibition recorded. Activity of the cell-free supernatant was assayed for by a modification of the critical dilution method generally used for assay of bacteriocins (Mayr-Harting et al., (1972) supra). Serial dilutions were spotted (5 μl) onto freshly seeded lawns of Ls. innocua,B. coagulans 1761 and L. fermentum KLD and the plates incubated appropriately. The titre was defined as the reciprocal of the highest dilution of inhibitor demonstrating complete inhibition of the indicator lawn and was expressed as activity units (AU) per millilitre (ml). - Microtitre Plate Assay:
- Bacteriocin activity was measured during the purification procedure by the microtitre plate assay as described by Holo, H., et al. (1991)J. Bacteriol. 173, 3879-3887. Two-fold serial dilutions of bacteriocin extracts (50 μl) in TSAYE broth were prepared in microtitre plates (Greiner GmbH, Frickenhausen). One hundred and fifty microlitres of fresh indicator culture (A600˜0.1) and 50 ∥l of TSAYE were added and the plates incubated at 37° C. Growth of the indicator strain was measured spectrophotometrically at 600 nm. One bacteriocin unit was defined as the amount of bacteriocin causing 50% growth inhibition (50% of the turbidity of the control culture without bacteriocin) in this assay.
- Bacteriocin Purification
- Ammonium Sulphate Precipitation:
-
L. salivarius 118 was grown to the late logarithmic phase in 2 l of MRS broth (Oxoid) and centrifuged at 12,000 rpm for 20 min. Ammonium sulphate (300 g/l) was added to the cell-free supernatant, stirred at 4° C. for 1 h, and centrifuged at 8,000 rpm for 30 min. The pellet and pellicle (floating solid material) were combined and dissolved in 100 ml H2O (Fraction I). - Hydrophobic Interaction Chromatography:
- Fraction I was mixed with 10 g of amberlite XAD-16 (Supelco) for 30-45 min applied to a column and washed once with H2O (100 ml) and then twice with 40% ethanol (100 ml). The bacteriocin was eluted from the column with 100 ml (10×10 ml) of 70% isopropanol-10 mM HCl (Fraction II).
- Fraction II was adjusted to pH 2-3 with H2O+0.1% trifluoroacetic acid (TFA) and immediately applied to a 2 ml S-Sepharose Fast Flow cation exchange column previously equilibrated with 5 mM sodium phosphate buffer, pH 5.4 (buffer A). After subsequent washing with 40 ml of buffer A, the bacteriocin was eluted with 20 ml of 1 M NaCl in buffer A (Fraction III).
- C2/C18 Reverse-Phase FPLC:
- Fraction III was applied to a C2/C18 reverse-phase FPLC column (Pep RPC) equilibrated with isopropanol containing 0.1% TFA, solution A. The bacteriocin was eluted with a linear gradient ranging from 30-37% solution A for 40 min. followed by a gradient 37-100% solution A for another 5 min. The flow rate was 0.5 ml/min and 1 ml fractions were collected. Each fraction was tested for activity using the microtitre plate assay. Fractions with high bacteriocin activity were mixed and rechromatographed on the reverse-phase column.
- Amino Acid Composition and Sequence Analysis
- The purified bacteriocin was hydrolyzed and analyzed on an amino acid analyzer as described previously (Fykse, E. M., et al., (1988)Biochem J. 256, 973-980). The amino acid sequence was performed by Edman degradation with an Applied Biosystems model 477A automatic sequencer with an on-line 120A phenylthriohydantoin amino acid analyser (Cornwell, G. G., et al., (1988) Biochem. Biophys. Res. Commun. 154, 648-653) The C-terminal part of the sequence was obtained after cleavage of the bacteriocin with cyanogen bromide (CnBr) (Sletten, K., et al., (1974) Eur. J. Biochem. 41, 117-125).
- Mode of Action of ABP118
- Adsorption Assays:
- Ability of ABP118 to adsorb to the cell wall of sensitive and resistant strains was investigated. Briefly, three overnight cultures ofLs. innocua,
L. salivarius UCC 118, L. fermentum KLD, E. coli 1266 andB. coagulans 1761 were each subcultured in fresh broth (20 ml) and grown to mid-logarithmic phase. Cells were harvested by centrifugation, washed twice in 50 mM sodium phosphate buffer, pH 6.5, and resuspended in buffers pH 4.0, 6.0 and 8.0 containing 2000 AU/ml of ABP118. The mixtures were incubated at 37° C. for 2 h. The cells were then removed by centrifugation and the antimicrobial titre of the supernatant was determined. Controls included incubation of 2000 AU/ml ofABP 118 with no cells and cells with noABP 118 added. - Bactericidal Versus Bacteriostatic Action of ABP118:
- Duplicates ofLs. innocua, L. fermentum KLD and
B. coagulans 1761 were grown to log-phase (OD600, 0.2-0.5). To one set ofcells 5000 AU/ml of ABP118 was added. The second set of cells were washed twice and resuspended in phosphate buffer, pH 6.5 prior to the addition of 5000 AU/ml of ABP118. Growth (cfu/ml) under the appropriate conditions, was monitored for a further 7-8 h. This experiment was repeated using stationary-phase cells. - Effect of ABP118 on DNA, RNA and Protein Synthesis of Sensitive Cells:
- The sensitive
indicator B. coagulans 1761 was inoculated (3% (v/v)) into TSAYE growth medium and grown to early log phase (3-4 h) at 37° C. The culture was divided in two. To onehalf 5000 AU/ml of antimicrobial compound was added while an equivalent volume of growth medium was added to the other half. Each half was then supplemented with a radiolabelled substrate. The following substrates (New England Nuclear Corps.) were used: [5,6-3H]uridine (39.6 Ci/mmol) at 5 μCi/ml;. methyl [3H]thymidine (6.7 Ci/mmol) at 5 μCi/ml and L-[35S]methionine (1175 Ci/mmol) at 5 μCi/ml. At regular intervals, samples were removed from the cultures and growth medium added (pH 5.8). Each sample was then supplemented with 15% trichloroacetic acid (TCA), mixed well and incubated on ice for 18 h. The samples were then filtered through glass fiber filters and washed with 5% TCA and dried. Filters were placed in scintillation vials with Beckman Ecolite scintillatant and counted in a Beckman liquid scintillation counter. - Purification of ABP118
- ABP118, which is produced in the log-phase of growth (see Example 5), was concentrated 20-fold from culture media by ammonium sulphate precipitation (Fraction I) resulting in a 292-fold increase in specific activity with a recovery of 250% as shown in Tables 11 and 12.
TABLE 11 Purification of ABP118 Vol. Total* Total act. Purification stage (ml) A280 (BU) Culture supernatant 2000 54,800 5,120,000 Fraction I Ammonium suphate ppt. 470 12,800,000 II Hydrophobic 51 192,000 (interaction (XAD-16) III Cation exchange 5.98 6,400 IVC2/C18 Reverse-phase 1.5 0.192 2,400 FPLC -
TABLE 12 Purification of ABP118 Increase in sp. act. Yield Purification stage Sp. act.* (fold) (%) Culture supernatant 93 1 100 Fraction I Ammonium suphate ppt. 27,234 292 250 II Hydrophobic 3,765 40 3.75 (interaction (XAD-16) III Cation exchange 1,070 12 0.13 IVC2/C18 Reverse-phase 12,500 135 0.047 FPLC - After passing through the hydrophobic XAD-16 column, there was a dramatic loss in specific activity with a yield of 3.75% (Table 12, Fraction II). The final purification step resulting in pure ABP118 was reverse-phase chromatography. The active peak, collected as one fraction, eluted at a concentration of 100% isopropanol. When this peak was reapplied to the column, the pure active peak eluted at 31.5% isopropanol. The specific activity of pure ABP118 was 135-fold greater than the culture supernatant and final recovery was 0.047% (Table 12, Fraction IV). Passing through a cation exchange column prior to FPLC decreased specific activity (Table 12, Fraction III) but resulted in better purification. The final protein concentration was estimated to be 130 μg/ml.
- Amino Acid Composition and Sequence Analysis
- The amino acid composition of pure ABP118 was determined as shown in Table 13.
TABLE 13 Amino acid composition of ABP118 Amino acid residues/molecules Asp/ Asn 4 Glu/ Gln 2 Ser 1-2 Gly 8-10 His 0-1 Arg 2 Thr 2 Ala* 6 Pro* 4 Met* 1 Cys 1 Ile* 1 Leu* 5 Phe* 2 Lys 2 Val 2 Total 43-47 - No unusual amino acids were detected. A high proportion of glycine, alanine and leucine was found. No tryptophan or tyrosine residues were present. On Edman degradation, the N-terminus was blocked. As one methionine residue was present, cyanogen bromide cleavage was performed and five amino acid residues were determined at or adjacent to the N-terminus, -Lys-Arg-Gly-Pro-Asn-C (SEQ ID NO: 1). Of the 43-47 amino acids, twenty-one were hydrophobic. The ability to undergo cyanogen bromide cleavage is indicative of the presence of the methionine residue upstream of the lysine residue at the N-terminus.
- Mode of Action of ABP118
- ABP118 Adsorbs to Sensitive Cells:
- Adsorption of ABP118 was tested over the pH range 4.0-8.0. It was observed that ABP118 bound to the sensitive cells tested (see Table 14) but not to the resistant producer strain
L. salivarius UCC 118.TABLE 14 Adsorption of ABP118 (1600 AU/ml) to sensitive and resistant cells under different pH conditions* ABP118 (AU/ml) unadsorbed Strain pH 4.0 pH 6.0 pH 8.0 Lactobacillus 1000 (40%) 800 (50%) 800 (50%) fermentum KLD (S) L. salivarius 1600 (0%) 1600 (0%) 1600 (0%) UCC 118 (R) Escherichia 1600 (0%) 1600 (0%) 800 (50%) coli 1266 (R) Bacillus 1000 (40%) 1000 (40%) 1000 (40%) coagulans 1761 (S) Listeria 1000 (40%) 1000 (40%) 1000 (40%) innocua (S) - ABP118 binding toE. coli 1266 was observed at pH 8.0 but not at the lower pH values tested. After 2 h incubation at 37° C., 40% adsorption of ABP118 to sensitive cells was measured, Total adsorption of 100% was never observed. Less adsorption was found when the experiment was repeated at 4° C. When cells were autoclaved, 40% adsorption was recorded for both sensitive and resistant cells. When cells were treated with protease there was little increase in adsorption to either sensitive or resistant cells.
- ABP118 Possesses both Bactericidal and Bacteriostatic Activity:
- The inhibitor ABP118 is bactericidal in nature. The most impressive example of this was the effect ABP118 had on the growth ofB. coagulans 1761 during both the log-, and stationary-phase of growth (on both unwashed and washed cells; see FIGS. 5A-5D). The broth cleared during the first couple of hours after addition of ABP118 demonstrating the lytic activity of ABP118. The bactericidal activity towards Ls. innocua and L. fermentum KLD was more evident in the log-phase of growth than in the stationary-phase. It was noticed that a rapid decline in KLD strain cell viability occurred after incubation of stationary-phase cells for 4 h after the addition of ABP118. The activity of ABP118 (5000 AU/ml) was also tested against a Gram negative P. fluorescens strain and a methicillin resistant S. aureus strain. After 60-90 min incubation a bacteriostatic effect on the growth of both strains was clearly evident (FIGS. 6 and 7). After 1 h incubation at 30/37° C. the cells were divided in two, ABP118 added to one portion (arrows), and growth was monitored for a further 8-9 h. The line →-→illustrates the bacteriostatic effect of ABP118.
- ABP118 Inhibits DNA and RNA Synthesis:
- Addition of 5000 AU/ml of ABP118 to log-phase cells did not result in incorporation of either thymidine or uridine indicating that there was inhibition of synthesis of the macromolecules DNA and RNA, respectively. When no bacteriocin was added, cells actively incorporated thymidine and uridine. Inhibition of protein synthesis was not demonstrated due to the low incorporation of radiolabelled amino acid in both the test and control (probably as a result of the high concentration of free amino acids normally present in TSAYE medium). The results are shown in FIG. 8A and FIG. 8B.
- Amino Acid Composition and Sequence Analysis of ABP1
- The procedure followed in Example 6 in obtaining the amino acid composition for ABP118 was repeated so as to determine the amino acid composition of pure ABP1. The amino acid composition is shown in Table 15.
TABLE 15 Amino acid composition of ABP1 Amino acid residues/molecules Asp/ Asn 5 Glu/ Gln 6 Ser 5-6 Gly 8-9 His 1 Arg 2-3 Thr 2 Ala* 4-5 Pro* 2 Ile* 1-2 Leu* 3 Phe* 1 Lys 3 Tyr 1 Val* 2-3 Total 46-52 - As for ABP118 no unusual amino acids were detected. A high proportion of glycine and alanine was found and a relatively high proportion of leucine. No trytophan was found, however tyrosine and valine were found. Of the 46-52 amino acids, 13-16 were hydrophobic.
- Sequence of ABP118
- Total genomic DNA was isolated from UCC118 grown in MRS supplemented with 40 mM DL-threonine by the method of Leenhouts et al. 1991 (J. Bacteriol. 173:4794-4798) and purified by CsCl-ethidium bromide buoyant density gradient centrifugation, with the following modifications. After pelleting and washing the cells in STE buffer, pH 8.0 (6.7% Sucrose, 50 mM Tris/HCl. ImM EDTA), the repelleted cells were stored at −20° C. o/n. The cells were lysed using 8 mg/ml lysozyme and 50 U/ml mutanolysin on ice for 1 hour and then incubated at 37° C. for 45 minutes. Before adding SDS solution, 2 mg/ml of proteinase K was added and incubated at 55° C. for 1 hour.
- Total genomic DNA for UCC118 was digested with BamHI restriction endonuclease according to the manufacturer's directions (Boehringer Mannheim). Oligonucleotide primers were synthesised on a Beckma Oligo 1000 M DNA synthesizer. A fragment encompassing the putative structural gene of ABP118 was amplified by the polymerase chain reaction (PCR) using BIOTAQ™ polymerase (Bioline) and was subsequently purified from an agarose gel using the Qiaex II gel extraction kit (Quagen). Cloning was performed in the pGEM-T vector system (Promega) followed by transformation intoE. Coli JM109 competent cells. Potential pGEM-T recombinants were identified by blue-white screening, using isopropyl-β-D-thiogalactoside and 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal). The presence of inserts was confirmed by PCR using the pGEM-T sequencing primers designed to the known sequences of the T7 and SP6 promoters. These PCR amplified fragments were sequenced by the automated DNA sequencer 373 stretch XL (PE Applied Biosystems) using the Dye terminator cycle sequencing ready reaction kit with Ampli Taq DNA polymerase, FS (Applied Biosystems).
- Following cyanogen bromide cleavage and subsequent sequencing, a 30 amino acid sequence from the C-terminal region of ABP118 was obtained including 1 amino acid which could not be identified as indicated below.
(SEQ ID NO: 3) Asn Met Lys Arg Gly Pro Asn ? Val* Gly Asn Phe* Leu Gly* Gly Leu Phe Ala Gly Ala* Ala* Ala* Gly Val Pro Leu* Gly Pro-(Ala-Gly-Ile)-Cys. *indicates probability of more than one amino acid species at positions 8, 11, 13, 19 20, 21 and 25?unidentified amino acid ( )indicates possibility of wrong sequence - This sequence was confirmed by PCR with BamHI restricted total DNA using degenerate primers, the forward primers (5′ATGAAACGNGGNCCNAAC3′) (SEQ ID NO: 4) being designed to the first six known N-terminal amino acids whereas the reverse primer (5′ GGGCCTRNGGNACNCC3′) (SEQ ID NO: 5) was designed to amino acids 21 to 26, wherein R=purine. An 80 bp. fragment was isolated and subsequently sequenced as follows,
(SEQ ID NO: 6) 5′ATGAAACGCGGACCCAACTGTGTAGGTAACTTCTTAGGTGGTCTATTT GCTGGAGCAGCTGCAGGTGTCCCCCAAGGGCCC3 - This DNA sequence was deducted to give the following protein sequence thus confirming the identity of amino acids at
positions (SEQ ID NO: 2) Asn Met Lys Arg Gly Pro Asn Cys Val Gly Asn Phe Leu Gly Gly Leu Phe Ala Gly Ala Ala Ala Gly Val Pro Gln Gly Pro Cys. - The DNA sequence showed no homology to known sequences in the data banks.
-
1 6 1 5 PRT Lactobacillus salivarius 1 Lys Arg Gly Pro Asn 1 52 29 PRT Lactobacillus salivarius 2 Asn Met Lys Arg Gly Pro Asn Cys Val Gly Asn Phe Leu Gly Gly Leu 1 5 10 15 Phe Ala Gly Ala Ala Ala Gly Val Pro GlnGly Pro Cys 20 253 32 PRT Lactobacillus salivarius misc_feature (1)..(32) any Xaa between residues 1-32 is unknown or other 3 Asn Met Lys Arg Gly Pro Asn Xaa Val Gly Asn Phe Leu Gly Gly Leu 1 5 10 15 Phe Ala Gly Ala Ala Ala Gly Val Pro Leu Gly Pro AlaGly Ile Cys 20 25 304 18 DNA Artificial Sequence primer derived from Lactobacillus salivarius 4 atgaaacgng gnccnaac 185 16 DNA Artificial Sequence primer derived from Lactobacillus salivarius 5 gggcctrngg nacncc 16 6 80 DNA Lactobacillus salivarius 6 atgaaacgcg gacccaactg tgtaggtaac ttcttaggtg gtctatttgc tggagcagct 60 gcaggtgtcc cccagggccc 80
Claims (8)
1. An antimicrobial agent obtained from a strain of Lactobacillus salivarius isolated from resected and washed human gastrointestinal tract which inhibits a broad range of Gram positive and Gram negative microorganisms and which secretes a product having antimicrobial activity into a cell—free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E, the inhibitory properties of said strain and its secretory products being maintained in the presence of physiological concentrations of human bile and human gastric juice, which has bacteriocin—like properties.
2. An antimicrobial agent according to claim 1 , which has the following properties:
(i) An apparent molecular weight between,30 and 100 kDa;
(ii) Heat stability;
(iii) Resistance over a wide pH range;
(iv) Resistance to treatment with detergents;
(v) Resistance to organic solvents;
(vi) Sensitivity to proteolytic enzymes including proteinase K, pronase E, trypsin, α-chymotrypsin, ficin and papain; and
(vii) Resistance to lipase, catalase, alkaline phosphatase, phospholipase C and lipoprotein lipase.
3. A purified fraction of an antimicrobial agent according to claim 2 , which has the following properties:
(i) A molecular weight of 5.0-5.3 kDa;
(ii) A relative amino acid composition which has greater than 45% of hydrophobic amino acids, 19-21% glycine, 13-14% alanine and 11-12% leucine, no tryptophan or tyrosine, one methionine and four proline residues;
(iii) An amino acid sequence SEQ ID NO: 1 at or adjacent to the N-terminus; and
(iv) Comprises an amino acid sequence SEQ ID NO: 2.
4. A purified fraction of an antimicrobial agent according to claim 2 , which has the following properties:
(i) A molecular weight of 5.3-6.1 kDa; and
(ii) A relative amino acid composition which has greater than 28-30% of hydrophobic amino acids, 17% glycine and 12-13% alanine, no tryptophan and two proline residues.
5. An antimicrobial agent according to any one of claims 1-4, for use in foodstuffs.
6. An antimicrobial agent according to any one of claims 1-4, for use as a medicament.
7. An antimicrobial agent according to any one of claims 1-3, for use against methicillin resistant S. aureus (MRSA).
8. The DNA sequence SEQ ID NO: 6 coding for bacteriocin ABP118.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/603,865 US20040038379A1 (en) | 1997-02-11 | 2003-06-26 | Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE9700007 | 1997-02-11 | ||
WOPCT/IE97/00007 | 1997-02-11 | ||
US36710599A | 1999-11-10 | 1999-11-10 | |
US10/603,865 US20040038379A1 (en) | 1997-02-11 | 2003-06-26 | Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IE1998/000010 Division WO1998035014A2 (en) | 1997-02-11 | 1998-02-11 | Probiotic strains from lactobacillus salivarius and antimicrobial agents obtained therefrom |
US09367105 Division | 1999-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040038379A1 true US20040038379A1 (en) | 2004-02-26 |
Family
ID=11042502
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/603,865 Abandoned US20040038379A1 (en) | 1997-02-11 | 2003-06-26 | Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
US10/606,114 Expired - Fee Related US7186545B2 (en) | 1997-02-11 | 2003-06-26 | Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/606,114 Expired - Fee Related US7186545B2 (en) | 1997-02-11 | 2003-06-26 | Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom |
Country Status (12)
Country | Link |
---|---|
US (2) | US20040038379A1 (en) |
EP (1) | EP1002051B1 (en) |
JP (1) | JP4743925B2 (en) |
AT (1) | ATE496989T1 (en) |
AU (1) | AU748744B2 (en) |
CA (1) | CA2280704A1 (en) |
DE (1) | DE69842112D1 (en) |
ES (1) | ES2360341T3 (en) |
MX (1) | MXPA99007378A (en) |
NO (1) | NO993818L (en) |
NZ (1) | NZ337505A (en) |
WO (1) | WO1998035014A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007070518A2 (en) * | 2005-12-13 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Bacteria-derived blis for treatment of acne |
EP1858534A2 (en) * | 2005-03-18 | 2007-11-28 | The United States of America, as represented by The Secretary of Agriculture | Bacteriocins and novel bacterial strains |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
DE19844469A1 (en) * | 1998-09-28 | 2000-03-30 | Herzog Mesmer Artur | Production of an antimicrobial agent useful for pharmaceutical or disinfectant purposes comprises culturing a bacterium, washing the culture and heat treating the wash liquid |
ID29150A (en) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | USE OF LACTOBACILLUS SALIVARIUS |
US6264967B1 (en) * | 1999-07-14 | 2001-07-24 | Shinei Fermentec Corporation | Method for eliminating Staphylococcus aureus, novel microorganism of genus Brachybacterium, and care garment, care sheet or care bedclothes, each being immobilized with microorganism of genus Brachybacterium |
EP1212066A4 (en) * | 1999-08-09 | 2004-03-03 | Univ Maryland | Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids |
EP1148064A1 (en) * | 2000-04-17 | 2001-10-24 | Vrije Universiteit Brussel | Lactobacillus johnsonii bacteriocin, active against Helicobacter pylori |
AU2001256610A1 (en) * | 2000-05-12 | 2001-11-20 | Alimentary Health Limited | A probiotic adhesin product, derived from lactobacillus |
WO2002083879A2 (en) * | 2001-04-02 | 2002-10-24 | Alimentary Health Limited | Immunotherapy based on dendritic cells |
JP4671384B2 (en) * | 2001-05-15 | 2011-04-13 | 雪印乳業株式会社 | New lactic acid strain |
PE20030283A1 (en) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | LACTOBACILLUS CASEI STRAINS |
PE20030274A1 (en) | 2001-07-26 | 2003-05-08 | Alimentary Health Ltd | LACTOBACILLUS SALIVARIUS STRAINS |
GB0124580D0 (en) | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
KR100585392B1 (en) * | 2002-01-24 | 2006-05-30 | 주식회사 프로바이오닉 | Acid tolerant probiotic Lactobacillus slivarius Probio-37 that can suppresses the growth of pathogenic microorganisms and TGE coronavirus |
US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
IL152219A0 (en) * | 2002-10-10 | 2003-05-29 | Univ Ramot | Identification and modulation of intermediates of alcohol metabolism |
WO2004104175A2 (en) * | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
US7132102B2 (en) * | 2003-08-21 | 2006-11-07 | The United States Of America As Represented By The Secretary Of Agriculture | Bacteriocins and novel bacterial strains |
CN101001635A (en) * | 2003-12-04 | 2007-07-18 | 生物膜策略公司 | Methods and compositions for preventing biofilm formation, reducing existing biofilms, and for reducing populations of bacteria |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
ES2262418B1 (en) * | 2004-12-28 | 2007-11-01 | Consejo Superior Investig. Cientificas | PROTEIN EXTRACTS WITH LARGE SPECTRUM OF ANTIBACTERIAL ACTIVITY AND BIFIDOBACTERIUM GENDER STRAINS THAT PRODUCE THEM. |
US20060228448A1 (en) | 2005-04-11 | 2006-10-12 | The Iams Company | Pet food compositions comprising two components |
EP2261323A1 (en) | 2005-05-31 | 2010-12-15 | The Iams Company | Feline probiotic lactobacilli |
PL1885383T3 (en) | 2005-05-31 | 2017-06-30 | Iams Europe B.V. | Feline probiotic bifidobacteria |
EP1862080A1 (en) * | 2006-05-31 | 2007-12-05 | Ajinomoto Co., Inc. | Protease-resistant bacteriocins produced by lactic acid bacteria and their use in livestock |
MX2009006808A (en) * | 2006-12-22 | 2010-04-01 | Bio K Plus Internat Inc | Growth inhibition and elimination of methicillin-resistant staphylococcus aureus by lactic acid bacteria. |
WO2008093303A2 (en) | 2007-02-01 | 2008-08-07 | The Iams Company | Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts |
KR100818360B1 (en) | 2007-03-16 | 2008-04-02 | 건국대학교 산학협력단 | Novel Lactobacillus plantarum the culture medium producting therefor and the composition comprising the same |
FI20080321A0 (en) * | 2008-04-25 | 2008-04-25 | Eino Elias Hakalehto | Procedure for maintaining bacterial balance in the intestinal tract |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US9200251B1 (en) | 2011-03-31 | 2015-12-01 | David Gordon Bermudes | Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith |
EP2551279A1 (en) | 2011-07-27 | 2013-01-30 | University College Cork | Antimicrobial peptide produced by intestinal Lactobacillus salivarius |
KR101353084B1 (en) * | 2011-12-30 | 2014-01-17 | 대한민국 | Lactobacillus salivarius isolated from poultry feces |
FR2999601B1 (en) * | 2012-12-17 | 2015-01-30 | Urgo Lab | METHOD FOR PREVENTING AND / OR TREATING INFECTIONS, COLONIZATIONS OR DISEASES ASSOCIATED WITH STAPHYLOCOCCUS AUREUS, PSEUDOMONAS AERUGINOSA, STREPTOCOCCUS PYOGENES, ENTEROCOCCUS FAECIUM, ENTEROBACTER CLOACAE, PROTEUS MIRABILIS AND / OR BACTEROIDES FRAGILIS |
WO2016130981A1 (en) | 2015-02-13 | 2016-08-18 | Mars, Incorporated | Pet food feeding system |
US9730969B2 (en) | 2015-11-06 | 2017-08-15 | Mead Johnson Nutrition Company | Nutritional compositions for promoting gut barrier function and ameliorating visceral pain |
CN106498025A (en) * | 2016-11-07 | 2017-03-15 | 湖南益旺生物科技有限公司 | Biologic product culture medium additive and production method and application in the medium |
DK3517119T3 (en) | 2018-01-26 | 2021-11-15 | Probisearch S L U | Composition comprising new lactobacillus salivarius strain and method for the prevention and treatment of otitis and upper respiratory tract infections |
US20220226382A1 (en) | 2019-06-05 | 2022-07-21 | Morinaga Milk Industry Co., Ltd. | Nutritional Composition |
CN110643544B (en) * | 2019-11-01 | 2021-05-14 | 四川农业大学 | Lactobacillus paracasei761, application thereof, silage additive and silage |
JP2023068430A (en) * | 2021-11-02 | 2023-05-17 | 住友化学株式会社 | Antibacterial peptide |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4347240A (en) * | 1979-02-27 | 1982-08-31 | Kabushiki Kaisha Yakult Honsha | Antitumor agent containing Lactobacillus casei YIT 9018 |
US5032399A (en) * | 1985-04-17 | 1991-07-16 | Sherwood L. Gorbach | L. acidophilus strains |
US6077504A (en) * | 1996-06-28 | 2000-06-20 | Cavaliere Ved. Vesley; Renata Maria Anna | Enteral dietary compositions comprising a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis |
US6132710A (en) * | 1997-03-17 | 2000-10-17 | Probiotix, Inc. | Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK686187D0 (en) * | 1987-12-23 | 1987-12-23 | Hansens Chr Bio Syst | VETERINATED PREPARATION |
DE68928665T2 (en) | 1988-08-02 | 1998-11-12 | Gastro Services Pty Ltd | TREATING GASTRO-INTESTINAL DISEASES |
SE8900546D0 (en) | 1989-02-17 | 1989-02-17 | Bioinvent Int Ab | Means for inhibiting pathogens' growth and / or survival |
NZ232512A (en) * | 1989-02-21 | 1993-09-27 | Viskase Corp | Compositions and firms containing antibacterial agents, methods of treating foodstuffs therewith |
JP4021951B2 (en) | 1996-03-01 | 2007-12-12 | わかもと製薬株式会社 | Anti-gastritis, anti-ulcer and fermented food containing lactic acid bacteria as active ingredients |
US5902578A (en) | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
AUPR438601A0 (en) | 2001-04-11 | 2001-05-17 | Cochlear Limited | Variable sensitivity control for a cochlear implant |
-
1998
- 1998-02-11 DE DE69842112T patent/DE69842112D1/en not_active Expired - Lifetime
- 1998-02-11 CA CA002280704A patent/CA2280704A1/en not_active Abandoned
- 1998-02-11 JP JP53406598A patent/JP4743925B2/en not_active Expired - Fee Related
- 1998-02-11 NZ NZ337505A patent/NZ337505A/en unknown
- 1998-02-11 MX MXPA99007378A patent/MXPA99007378A/en active IP Right Grant
- 1998-02-11 AT AT98904350T patent/ATE496989T1/en not_active IP Right Cessation
- 1998-02-11 AU AU62275/98A patent/AU748744B2/en not_active Ceased
- 1998-02-11 WO PCT/IE1998/000010 patent/WO1998035014A2/en active Search and Examination
- 1998-02-11 EP EP98904350A patent/EP1002051B1/en not_active Expired - Lifetime
- 1998-02-11 ES ES98904350T patent/ES2360341T3/en not_active Expired - Lifetime
-
1999
- 1999-08-06 NO NO19993818A patent/NO993818L/en not_active Application Discontinuation
-
2003
- 2003-06-26 US US10/603,865 patent/US20040038379A1/en not_active Abandoned
- 2003-06-26 US US10/606,114 patent/US7186545B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4347240A (en) * | 1979-02-27 | 1982-08-31 | Kabushiki Kaisha Yakult Honsha | Antitumor agent containing Lactobacillus casei YIT 9018 |
US5032399A (en) * | 1985-04-17 | 1991-07-16 | Sherwood L. Gorbach | L. acidophilus strains |
US6077504A (en) * | 1996-06-28 | 2000-06-20 | Cavaliere Ved. Vesley; Renata Maria Anna | Enteral dietary compositions comprising a mixture of live lactic bacteria consisting of Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium infantis |
US6132710A (en) * | 1997-03-17 | 2000-10-17 | Probiotix, Inc. | Preventing/treating neonatal NEC by administering lactobacillus salivarius and lactobacillus plantarum or a combination thereof |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1858534A2 (en) * | 2005-03-18 | 2007-11-28 | The United States of America, as represented by The Secretary of Agriculture | Bacteriocins and novel bacterial strains |
EP1858534A4 (en) * | 2005-03-18 | 2009-07-22 | Us Agriculture | Bacteriocins and novel bacterial strains |
WO2007070518A2 (en) * | 2005-12-13 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Bacteria-derived blis for treatment of acne |
WO2007070518A3 (en) * | 2005-12-13 | 2008-05-22 | Univ Pennsylvania | Bacteria-derived blis for treatment of acne |
US20100056423A1 (en) * | 2005-12-13 | 2010-03-04 | The Trustees Of The University Of Pennsylvania | Bacterial-Derived BLIS for Treatment of Acne |
US8415289B2 (en) | 2005-12-13 | 2013-04-09 | The Trustees Of The University Of Pennsylvania | Bacterial-derived BLIS for treatment of acne |
Also Published As
Publication number | Publication date |
---|---|
EP1002051A2 (en) | 2000-05-24 |
NZ337505A (en) | 2001-07-27 |
US7186545B2 (en) | 2007-03-06 |
AU6227598A (en) | 1998-08-26 |
ATE496989T1 (en) | 2011-02-15 |
JP2002514068A (en) | 2002-05-14 |
US20040214304A1 (en) | 2004-10-28 |
CA2280704A1 (en) | 1998-08-13 |
DE69842112D1 (en) | 2011-03-10 |
EP1002051B1 (en) | 2011-01-26 |
NO993818D0 (en) | 1999-08-06 |
ES2360341T3 (en) | 2011-06-03 |
JP4743925B2 (en) | 2011-08-10 |
AU748744B2 (en) | 2002-06-13 |
WO1998035014A3 (en) | 1998-11-19 |
NO993818L (en) | 1999-10-11 |
WO1998035014A2 (en) | 1998-08-13 |
MXPA99007378A (en) | 2005-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7186545B2 (en) | Probiotic strains from Lactobacillus salivarius and antimicrobial agents obtained therefrom | |
Prabhurajeshwar et al. | Probiotic potential of Lactobacilli with antagonistic activity against pathogenic strains: An in vitro validation for the production of inhibitory substances | |
Du Toit et al. | Characterisation and selection of probiotic lactobacilli for a preliminary minipig feeding trial and their effect on serum cholesterol levels, faeces pH and faeces moisture content | |
Thapa et al. | Microbial diversity in ngari, hentak and tungtap, fermented fish products of North-East India | |
Oh et al. | Characterization and purification of a bacteriocin produced by a potential probiotic culture, Lactobacillus acidophilus 30SC | |
Todorov et al. | Bacteriocin production and resistance to drugs are advantageous features for Lactobacillus acidophilus La-14, a potential probiotic strain | |
Aslam et al. | Isolation of acidophilic lactic acid bacteria antagonistic to microbial contaminants | |
Gupta et al. | Incidence of virulence in bacteriocin-producing enterococcal isolates | |
Sifour et al. | Production and Caracterization of Bacteriocin of Lactobacillus plantarum F12 with Inhibitory Activity against Listeria monocytogenes | |
Bhattacharya et al. | Study of Physical and Cultural Parameters on the Bacteriocins Produced by Lactic Acid Bacteria Isolated from | |
Ar et al. | Assessment of potential probiotic properties lactic acid bacteria from shrimp paste or belacan | |
Fadare et al. | Antimicrobial properties, safety, and probiotic attributes of lactic acid bacteria isolated from Sauerkraut | |
US20070280914A1 (en) | Method and use of a lactic acid bacteria with increased acid tolerance | |
US20020081311A1 (en) | Probiatic product | |
KR100720025B1 (en) | Probiotic lactic acid bacteria and composition comprising the same | |
JP3034451B2 (en) | Intestinal lactic acid bacteria and unheated meat products using the same | |
Al-Taie et al. | Optimization, purification, and characterization of enterocin SH1 produced by E. faecium SH1 and enterocin SH2 produced by E. faecalis SH2 isolated from dental caries | |
Movsesyan et al. | Properties and survival under simulated gastrointestinal conditions of lactic acid bacteria isolated from Armenian cheeses and matsuns | |
Lee et al. | Potential probiotic properties of Lactococcus lactis NK34 isolated from jeotgal | |
Anitha et al. | Isolation, molecular identification, and investigation of the probiotic potential of lactic acid bacteria isolated from Psidium guajava | |
Narakaew et al. | Preliminary characterization of Lactobacillus salivarius K7 for probiotic properties | |
JP3783187B2 (en) | Novel Lactobacillus lactic acid bacteria and cultures thereof | |
Kittaporn et al. | Study for probiotic properties of Lactobacillus salivarius KL-D4 isolated from duck intestine. | |
KR100720024B1 (en) | Probiotic bifidobacterium boum r5 strain and composition comprising the same | |
شادان عباس الونداوي | Antibacterial activity of Bacteriocins isolated from infant Lactobacillus against Listeria monocytogenes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |